WE’RE CHANGING HOW THE WORLD TREATS CANCER.
CONTENTS

Message from the Chairman and the President 03

WE’RE CHANGING HOW THE WORLD TREATS CANCER BY
BUILDING RELATIONSHIPS 06

WE’RE CHANGING HOW THE WORLD TREATS CANCER WITH
BOLD ADVANCES 16

PIONEER/PRIME MOVER:
JOHN GUNN
30 YEARS OF CHANGING HOW THE WORLD TREATS CANCER 42

Statistical Profile 50
Financial Summary 52
Boards of Overseers and Managers 54
Leadership 55
Facilities Update 57
The Campaign for Memorial Sloan Kettering 58
Donors to the Campaign for Memorial Sloan Kettering 59
The Society of Memorial Sloan Kettering Cancer Center 72
It denotes making groundbreaking discoveries and practice-changing treatment advances. It also suggests sharing that knowledge with as many people as possible.

At Memorial Sloan Kettering, we’ve created new ways to facilitate more discoveries, even more rapidly. We’ve also put in place creative new approaches to sharing — reaching within our own walls and beyond them to move what we know about cancer research, treatment, and care delivery into an ever-expanding universe of patients and fellow clinicians and scientists.

We aspire to touch the lives of as many patients as possible and to forge new collaborations with colleagues who will join with us in changing how the world treats cancer.
The theme of our Annual Report this year is *It's time we changed how the world treats cancer.* At MSK, we’re making decisive progress toward this goal, transforming how research is done, how care is delivered, and how treatments are personalized to each individual’s disease. In fact, changing how the world treats — and thinks about — cancer has been our mission for more than 130 years.

Today, scientific discovery in all its forms is constantly yielding new understanding of human biology. We now have the tools, technologies, and therapies to improve cancer prevention, diagnosis, and treatment. Much of this will come to life in the following pages.

Among the innovative ways in which we’re reshaping the conversation around cancer is through an array of new relationships and collaborations.

In 2014, the Hartford HealthCare Cancer Institute (HHCCI) became the first member of the MSK Cancer Alliance, an initiative designed to collaboratively guide community providers toward state-of-the-art cancer care. The concept emerged out of an awareness that community oncologists deliver the vast majority of cancer care in the United States, but that advances in treatment and research can take years to reach patients.

Among several distinctive aspects of the partnership is the establishment of an MSK Cancer Alliance clinical trials site, which will give physicians at HHCCI the opportunity to offer our pioneering clinical trials to their patients in Connecticut. (Read more about the MSK Cancer Alliance on page 9.)

Our basic-science, translational, and clinical-research enterprises excelled in 2014. New cross-disciplinary initiatives and collaborations both within MSK and beyond its walls contributed to advancing discovery.

The establishment of the Functional Genomics Initiative (FGI) is an effort to analyze the data produced by the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO). The CMO speeds the process by which genetic discoveries made through tumor analysis can be used to produce more-precise treatments for people with cancer. The FGI draws on the expertise of scientists and physicians in fields as diverse as stem cell science, molecular biology, and infectious disease to test new theories based on the genetic information flowing from the CMO. (For more on precision medicine, see “Cancer Genes Reveal Their Secrets” on page 10.)
A new genomic test developed by our researchers called MSK-IMPACT™ allows pathologists to screen more than 340 genes for cancer-causing mutations. In 2015, more than 10,000 MSK patients will have their cancer profiled using this test, which can detect gene mutations and other critical genetic aberrations in both rare and common cancers. The information gained will help physicians select personalized approaches to improve the effectiveness of each patient’s treatment.

In addition, we have entered into a collaborative relationship with Quest Diagnostics, a major provider of clinical diagnostic testing services, so that more patients can benefit from MSK’s clinical and research insights into genetic mutations associated with solid tumors. The aim is to use molecular laboratory testing to improve physicians’ ability to treat patients with breast, prostate, colon, lung, and a variety of other solid tumor cancers by giving them a better understanding of the genomic underpinnings of their patients’ illnesses. (Go to page 11 for more details on MSK-IMPACT and our partnership with Quest.)

As we gain a deeper understanding of the role of cellular differentiation and reprogramming in the pathogenesis of cancer, several members of our faculty have developed noteworthy new insights into how our bodies regulate the replacement or regeneration of damaged cells within individual organs. MSK’s new Center for Epigenetics Research (CER) will facilitate this work. The CER fosters inquiry in the rapidly growing fields of cancer epigenetics and epigenomics by bringing together MSK scientists and clinicians with different areas of expertise, including basic science discovery, translational cancer research and drug development, and the transfer of new ideas into early-phase clinical trials.

Immunology and immunotherapy are especially dynamic areas at MSK. The year opened with great excitement about the efficacy of reengineering immune cells to treat an aggressive form of leukemia. MSK also played a lead role in the clinical trials that led to FDA approval of new drugs that make it easier for the body’s immune system to recognize tumor cells as foreign. Great care has been put into the overall experience and comfort of both patients and caregivers — with private rooms, places to eat, and spaces to socialize, relax, and work — to create an environment specially designed for those who need to stay only a short time. (More details on the JRSC can be found in the Facilities Update on page 57.)

Then, in 2019, we expect to complete construction on the new complex we are developing jointly with The City University of New York/Hunter College on a site located between East 73rd and 74th Streets along the FDR Drive. The complex, for which we have now received all regulatory approvals, will play a critically important role in our outpatient cancer care delivery system.

We underwent several important transitions this year, beginning with the retirement of John Gunn, our Chief Operating Officer. He guided MSK for more than...
JOHN R. GUNN
Executive Vice President

30 years and served three successive presidents as an indispensable colleague and advisor. He has touched the lives of everyone in the MSK community: our staff, our patients and their families, and the city we serve. We owe him a tremendous debt of gratitude and wish him well in the next chapter of his life. (For more on his retirement, in his own words, read the interview “Pioneer/Prime Mover: 30 Years of Changing How the World Treats Cancer,” starting on page 43.)

As much as we will miss John, we have a worthy successor in Kathryn Martin. Formerly Executive Vice President and Chief Hospital Operating Officer, Kathryn joined MSK in 1999 as Senior Vice President and Hospital Administrator after serving in a variety of leadership roles at the New York Hospital before and after its merger with the Columbia Presbyterian Medical Center. Kathryn has been an extraordinary leader of Memorial Hospital, guiding its operations with skill, vision, and creativity, and we know she will continue to demonstrate her deep commitment to our institution.

We’re also delighted that Memorial Hospital Physician-in-Chief José Baselga was elected in 2014 to the Institute of Medicine (IOM). The IOM is a branch of the National Academies and was established to honor professional achievement in the health sciences. Membership is one of the highest honors in the fields of health and medicine. And, in another honor, Dr. Baselga was inaugurated President of the American Association for Cancer Research (AACR) at their annual meeting in April. The AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research.

We are equally excited about the international recognition that Sloan Kettering Institute Director Joan Massagüé received this year when he was awarded Spain’s highest scientific honor, the Spanish National Research Award, in recognition of his contributions to biomedical research. In addition, MSK led the list of most impactful cancer research centers in a ranking published by the prestigious scientific journal Nature.

MSK’s 2014 financial results met our expectations. Our operating revenues increased by 9.1 percent compared with our expense growth of 8.4 percent. A portion of the growth resulted from the opening of two new clinical facilities. During February 2015, MSK completed its financing program for the planned major clinical capital expansion (74th Street complex) at very favorable long-term interest rates. (See page 52 for more on MSK’s financials.)

For the 25th consecutive year, MSK was named a top hospital for cancer by U.S. News & World Report in its annual listing of Best Hospitals; we led the list as number one, an acknowledgement of our incomparable community. The tireless and selfless contributions of our staff, regardless of their roles within the institution, continue to ensure the highest level of patient satisfaction, clinical and research excellence, and a culture that supports caring, creativity, and discovery.

“More Science. Less Fear.” It’s the core creative concept of our new advertising campaign, launched in September 2014. And it’s really what Memorial Sloan Kettering is all about: defusing the fear surrounding cancer by doing the best basic and clinical science, leading to improved treatments and better outcomes for people with cancer everywhere.

As we advance into the future, our goal is nothing less than to revolutionize the treatment and understanding of the disease. In this year’s Annual Report, you’ll read about some of what we’ve mentioned only briefly in this message and will learn more about the remarkable men and women who are working to change the way the world treats cancer.

Douglas A. Warner III
Chair, Boards of Overseers and Managers

Craig B. Thompson
President and Chief Executive Officer
WE'RE CHANGING HOW THE WORLD TREATS CANCER BY BUILDING RELATIONSHIPS
Today, the majority of people with cancer receive their care outside a hospital. Memorial Sloan Kettering recognized this need for more convenient care as early as the 1990s, when we began establishing a network of suburban locations to bring the comprehensive services and unparalleled expertise of our staff closer to where our patients live and work. Our seventh location, MSK Monmouth, will open in Middletown, New Jersey, in 2016.

While mere miles may separate patients from Manhattan, shortening the physical distance between them and their doctors can mean avoiding a potentially long and often arduous commute. What it doesn’t mean is being separated from the MSK community. Patients at our suburban locations know they’re truly part of one family.

In 2014, MSK West Harrison — a 114,000-square-foot facility that’s home to a staff of 140 cancer surgeons, oncologists, radiologists, and other healthcare professionals — became the newest member to join that family.

“MSK West Harrison enables us to further extend the reach of our extraordinary cancer care, bringing the skill of our staff to patients where they live and work — in a serene, beautiful, and patient-friendly environment,” says Craig B. Thompson, MSK President and CEO. “And a key part of our mission is creating strong, long-lasting relationships with the community.”

No detail was overlooked in this modern, comfortable space designed to cater to all our patients’ needs. Amenities include valet parking, Wi-Fi, a grab-and-go fresh food counter, and a peaceful outdoor garden. And most importantly, MSK West Harrison provides care that is exactly the same as patients would receive if they were treated at any other MSK facility.

Specialized disease management teams offer diagnostic, treatment, and support services to people with breast, gynecologic, gastrointestinal, lung, urologic, and other cancers. MSK’s world-class surgeons provide
pre- and postsurgical care, and patients receive the latest chemotherapy treatments and the most advanced radiation therapies. Other offerings include genetic and nutrition counseling and social-work support.

“West Harrison was designed to extend the culture of MSK from the Manhattan site out to Westchester and the surrounding communities, so that we can bring what we’ve been doing in Manhattan to the local area,” explains Chau Dang, Chief of the Medical Oncology Service at MSK West Harrison.

“When we began thinking about clinicians who might want to work in West Harrison, rather than thinking only about hiring new people who may not be familiar with the MSK culture, we came up with a new model,” adds Richard Barakat, Deputy Physician-in-Chief for MSK’s Regional Care Network and Cancer Alliance. “We have physicians and surgeons and even chiefs of services who have been at MSK — in some cases for many years — who live in the community and who now work at MSK West Harrison. This allows us to truly infuse the MSK multidisciplinary culture into this new facility.”

“Physicians practicing at MSK West Harrison are thought leaders in cancer treatment and research, and many of them developed the current treatment standards in their respective fields,” says José Baselga, MSK’s Physician-in-Chief and Chief Medical Officer.

A wide range of clinical trials are available at MSK West Harrison. These include early-stage studies of novel targeted anticancer drugs and the specialized on-site staff and dedicated lab space that make those trials possible, allowing patients to both receive new treatments and schedule their follow-up appointments at the facility.

“Clinical trials are critical for translating scientific discoveries into new treatments that improve patient care,” says Ephraim Casper, Medical Director of MSK’s Regional Care Network. “For many, clinical trials offer the most promising treatment options available. The opportunity to participate in our trials is one of the special benefits of treatment at MSK, and patients who live in Westchester County, the Hudson Valley, and southwestern Connecticut will have access to the latest clinical trials close to home.”

Adding to patient convenience is an innovative relationship with the multispecialty Mount Kisco Medical Group (MKMG). People receiving treatment at MSK West Harrison can make appointments with MKMG physicians for non-oncology care, including cardiology, gastroenterology, pulmonology, gynecology, infectious disease, and internal medicine services — all without leaving the building.

AN ALLIANCE FUELS PROGRESS AGAINST CANCER

The MSK Cancer Alliance reaches beyond the walls of the institution in a different way, addressing the need to help ensure that the newest knowledge about cancer finds its way into the community. “Cancer advances can take years to be adopted in a community setting,” observes Dr. Baselga, who notes that ongoing relationships are needed to effectively close this gap.

A multihospital healthcare system in Connecticut, Hartford HealthCare (HHC), is the pioneering member of the MSK Cancer Alliance, which is designed to rapidly move innovative, evidence-based cancer care into the community setting and to enable bidirectional learning. “We’re building the MSK Cancer Alliance — beginning with our relationship with HHC — in the belief that we have something to learn from one another,” Dr. Thompson says. “This is definitely a two-way street.”

Among the many distinctive aspects of the collaboration will be the establishment of the MSK Cancer Alliance clinical trials site, which will give physicians at the Hartford HealthCare Cancer Institute the opportunity to offer MSK clinical trials to their patients in Connecticut.

“At the end of the day, patients and their families are the motivation behind everything we do,” says Dr. Thompson, “and this means building relationships like the one we’ve built with Hartford to create real change in improving cancer care and extending that care to wider patient populations.”
In order to treat a cancer effectively, you need to know as much as you can about what you’re treating. In recent years, it’s become clear that certain gene mutations influence the efficacy of cancer drug therapies — and that a therapy that may be effective for one type of cancer may also be useful for other types that share the same mutations.

President Barack Obama’s announcement in January 2015 of a precision medicine initiative addresses this issue of individual genetic variability and how its lessons can be applied to disease prevention and treatment across a wide range of conditions — with a near-term focus on oncology.

Oncology is an obvious choice for exploiting the promise of precision medicine. As we learn about each cancer’s own tumor-specific genetic features, individualized approaches to diagnosis — and a resulting revolution in treatment — are already becoming a reality. At Memorial Sloan Kettering, we’re moving further and further away from the paradigm of treating cancer as if it were one disease. Now, our goal is to treat individual cancers based on their specific mutational profile. But in order to successfully offer mutation-based therapies and strategies of targeted cancer prevention, we need to screen patients for the mutations of interest.

IT’S FOUNDATIONAL

Recently, MSK announced two new partnerships aimed at just that: giving our clinicians — and scientists everywhere — innovative cancer diagnostics. The first, with Foundation Medicine, brings together clinical, genomic, and computational expertise to advance patient care in hematologic (blood) cancers. The collaboration has focused on the co-development of a new Foundation Medicine molecular diagnostic product designed to match patients who have leukemia, lymphoma, or myeloma with the most-effective targeted therapies or clinical trials for their individual disease.

The new test — called FoundationOne™ Heme — analyzes blood samples from patients with these cancers and provides information about the hundreds of genes known to be associated with them. This genetic profile helps physicians make more-accurate prognoses and also guides clinical decision-making.

The profile may include data that can help decide whether taking an aggressive approach
with existing drugs is indicated or whether to enroll a patient in a clinical trial investigating a novel therapy.

Medical oncologist Ross Levine led the MSK research that contributed to the development of FoundationOne Heme along with physician-scientists Marcel van den Brink, Ahmet Dogan, and Scott Armstrong. The test now plays a central role in the clinical care of most patients with blood disorders at MSK and, it’s expected, will be used in the care of patients throughout the United States.

“Our hope is that the test will become available to all patients in the country with these malignancies,” says Dr. Levine. “We are excited that we aren’t just developing a tool for patients who are treated at MSK but also providing access to state-of-the-art genomics more broadly.”

The test analyzes more than 400 cancer-related genes and, unlike most standard tests, looks for alterations in both DNA and RNA. (RNA, one of two types of nucleic acid made by cells, contains information that has been copied from DNA — the other type of nucleic acid. Cells make several different forms of RNA, each with a specific job.) In addition to improving treatment for patients, MSK will use information gleaned from the tests to advance research into blood cancers.

QUESTING FOR MORE-ACCURATE DIAGNOSES

MSK’s second partnership is with Quest Diagnostics. The world’s leading provider of diagnostic information services, Quest will use our clinical and research insights into gene mutations associated with solid tumors. The goal is to employ molecular laboratory testing to improve physicians’ ability to treat patients with breast, prostate, colon, lung, and a variety of other solid tumors by giving them a better understanding of the genomic underpinnings of their patients’ illnesses.

The collaboration’s first phase involves MSK providing contextual information about individual mutations identified as part of Quest’s OncoVantage™, a test that enables molecular characterization of solid tumors. MSK has amassed vast databases of gene mutations linked to various types of cancers and has developed pharmaceutical treatments based on the scientific literature, therapies given to our patients, and clinical trials conducted here by our physicians and scientists.

MSK has extensive experience in this area over the past decade and has developed a pioneering test — called MSK-IMPACT™ — that can reliably and accurately screen for mutations in more than 400 genes. Tumors from MSK patients studied thus far have had on average between two and ten potentially actionable mutations; in other words, genomic changes that cause and contribute to a cancer’s growth and may respond to therapies targeting these underlying genomic alterations.

Physicians who order OncoVantage will benefit from the MSK data through a joint report designed to aid in the assessment of a patient’s progress, as well as to guide treatment selection and monitor disease progression.

“With unprecedented access to MSK’s knowledge of gene mutations in solid tumors and the therapies most effective in treating them, this relationship will empower clinicians to improve their patients’ health by identifying the best therapies for them and by identifying specific patients who may benefit from participation in clinical trials,” says Craig B. Thompson, MSK’s President and CEO. “The needs of tomorrow’s patients will also be addressed as, together with Quest, we deepen our knowledge base and its potential to help discover new therapies for people with cancer worldwide.”

Over time, MSK and Quest will further study and extend the mutation database to generate improved diagnostics, in addition to collaborating in research and clinical trials.
ENLISTING FAMILIES

One of the challenges of the practice of clinical cancer genetics today is the need to test dozens of cancer genes, some of which have recently been discovered and for which clinicians don’t have adequate information to guide preventive or treatment strategies. A newly formed consortium including experts from MSK, Dana-Farber Cancer Institute, Mayo Clinic, the Abramson Cancer Center of the University of Pennsylvania, and genetics laboratories nationwide has established the Prospective Registry of Multi-Plex Testing, or PROMPT, to address this challenge. PROMPT is an online registry for individuals and families who have undergone testing for inherited cancer-causing genetic mutations.

The registry seeks to provide data that are vital to improving the understanding of the level of risk associated with testing for panels of cancer-associated genes as well as outcomes following the tests. PROMPT offers a novel way for individuals, families, investigators, and labs to work together to accumulate the data needed to guide clinical decisions for people who have been or who will be found to carry mutations of these less commonly altered genes. Creating a database where patient information is gathered allows research teams from across the United States to better define the cancer risks associated with newly discovered genes and to measure the effects of cancer prevention studies in the future.

“The registry is designed in a flexible way that allows participants to choose how much personal information they provide,” explains medical oncologist Mark Robson, Clinic Director of the Clinical Genetics Service at MSK. “By participating in the study, even anonymously, families and individuals will increase the knowledge base not only for themselves but also for future generations that may be at risk because of these same genetic mutations.”

PROMPT has received initial funding from the Robert and Kate Neihaus Initiative in Clinical Cancer Genetics, based at MSK; the Basser Research Center at the University of Pennsylvania; and the Breast Cancer Research Foundation.

“We believe that PROMPT will provide an exciting new global model for using online portals to empower individuals to participate in ongoing genomics research to better target prevention in families at risk for cancer and other diseases,” says Kenneth Offit, Chief of MSK’s Clinical Genetics Service.

People can gain access to the PROMPT portal in several different ways: through crowdsourcing; on the project’s website, www.promptstudy.org; and via direct referral from genetic counselors and participating commercial testing labs.

EXCEPTIONAL RESPONDERS PROVIDE CLUES

Profound and sustained responses are often seen in only a small minority of patients enrolled in early-stage clinical trials of novel cancer agents, and investigators have long posited that these responses have a genetic basis. But until recently it wasn’t feasible to perform a comprehensive genomic analysis of such patients, who are known as exceptional responders.

Now, in collaboration with the New York Genome Center and 11 New York–based biomedical institutions, along with cancer researchers at Weill Cornell Medical College, MSK has launched the Exceptional Responder Initiative.

The initiative focuses on patients who have dramatic and durable responses to experimental cancer drugs in trials in which results are disappointing overall. “Statistically, these are negative studies. The drugs did not work for most patients,” explains physician-scientist David Solit, Director of the Marie-Josée and Henry R.
It’s not much of a stretch to compare cancer to a badly behaved child. Quiet, well-mannered cells rarely call attention to themselves. But when they act up — like unruly three-year-olds — they can wreak havoc. Man has always searched for ways to control cancer by cutting it out or poisoning it. More recently, we’ve deployed the power of the immune system and targeted drugs to help destroy the disease. But is there yet another way — perhaps by setting cancer back on a more normal course?

THE EPIGENOMIC LIBRARIAN

Our bodies are a stew of cell types. Billions of nerve cells transmit electric impulses throughout the brain. White blood cells called macrophages gobble up debris and dead bacteria. And star-shaped osteocytes dwell in the bone, some growing to be several decades old. In spite of their different tasks, these cell types — and about 200 others — have a common origin and share the same DNA.

So how can a single genetic blueprint, known as the genome, create so much diversity? For a long time, scientists thought the answer lay solely in the process of transcription, in which a segment of a cell’s DNA is copied into a molecule called RNA.

Much has been learned about cancer through the study of factors that regulate transcription over the last 40 years. But it has only recently become apparent that the regulation of gene expression is more complex than scientists previously imagined. How a brain cell chooses to activate one set of genes while a skin cell selects a different set has remained unclear.

An important part of the equation is the epigenome, an intricate system of chemical labels superimposed on DNA. These molecular labels govern how genes are expressed. In cancers, these labels can become altered, turning on genes that promote growth and turning off genes that suppress it.

Researchers are now applying techniques developed for deciphering the genome to decode the epigenome. In the process, they are uncovering new ways to think about cancer.

Kravis Center for Molecular Oncology and leader of the initiative. “But for the responding patients, the experimental agent was the ‘correct’ therapy. By analyzing these patients using next-generation sequencing methods, we have been able to identify genetic signatures that explain their dramatic drug sensitivity.”

Researchers then seek to identify other patients whose tumors have a similar genetic profile to these exceptional responders. The expectation is that many of these patients will be similarly responsive to the same therapy that was so effective in the outlier patients. “This approach has enabled us to resurrect therapies whose development was prematurely halted because the treatment showed little benefit in most patients,” says Dr. Solit. “In many cases, the approach has also identified new drug targets or areas of research that we’re now pursuing in the laboratory.”
annotations tell the cell which of the more than 20,000 genes in the genome should be turned off or on at any given moment. Each cell type has its own epigenetic program that shapes and maintains its identity.

“If we think of the genome as a library with thousands of books, the epigenome is the library’s indexing system or librarian,” explains Memorial Sloan Kettering President and CEO Craig B. Thompson, whose laboratory investigates how metabolic changes affect the epigenome. “Cells organize their DNA into bits of information that they access and use on a need-to-know basis. The epigenome provides a system through which each cell can identify the pieces of information it needs to access in order to maintain its identity.”

A host of diseases — including almost all types of cancer — have been linked to epigenetic programming errors. “There is now tremendous excitement about the possibility of developing a new type of cancer drug that manipulates a cell’s epigenome,” says physician-scientist Scott Armstrong, who directs MSK’s collaborative Center for Epigenetics Research.

STRAIGHTEN UP AND FLY RIGHT

Epigenetic therapies offer an unconventional treatment strategy. Rather than eliminate cancer cells — which is what most currently available treatments do — they seek to set the cells on a path back to normal growth and development.

At MSK, several such therapies have begun to show promising results for some patients enrolled in early-stage clinical trials, mainly for blood cancers. In addition, MSK investigators are developing novel drugs that could make it possible to curb a variety of tumor types by undoing specific epigenetic changes within them. Investigator Minkui Luo is exploring this new field of cancer science with an eye to being able to create a new drug that will one day help patients.

“I trained as a pure chemist,” says Dr. Luo, “and I knew very little about cancer before I came here.” However, since joining MSK in 2008, his research has taken him deep into the largely unexplored territory of epigenetics and cancer.

Dr. Luo’s laboratory investigates a family of enzymes called protein methyltransferases (PMTs), which tune the expression of many genes by modifying histones, the proteins that package DNA. Histones form disk-shaped structures around which a cell’s DNA strands are wrapped.

Collaborating with physician-scientist Yariv Houvras at Weill Cornell Medical College, Dr. Luo set out to explore the function of SET8, a PMT that had been implicated in cancer in a number of independent studies.

By screening a library of small drug compounds, Dr. Luo’s team developed two that could inhibit the activity of SET8. Working in a zebrafish model of melanoma developed in Dr. Houvras’s lab, they found that these compounds had powerful anticancer effects.

SEEING INTO THE HEART OF THE MATTER

Zebrafish, striped freshwater fish, naturally succumb to some of the same diseases as humans, including melanoma. They make elegant cancer research tools for a number of reasons, one being that their melanoma tumors are as dark as ink. Using just the naked eye, researchers can see cancers develop or watch tumors shrink in response to a drug.

“We got very excited when we found the SET8 inhibitor could block one of the key pathways known to drive melanoma,” Dr. Luo says. “Meanwhile, other scientists reported SET8 might also be involved in
metastatic breast cancer, so we knew we were onto something.”

PMTs regulate genes by adorning certain sites of histones and other molecules with chemical labels called methyl groups. Because these marks are so tiny (they’re a cluster of one carbon and three hydrogen atoms), PMT activity used to be very difficult to study, Dr. Luo says. But his lab has developed a technology — essentially a way to amplify molecular anatomy — that enables them to monitor the biochemical reactions.

Using this and other chemistry methods, they are working to optimize the pharmacological properties of the SET8 inhibitors, with the goal to generate a drug that could be tested in patients.

“The next step is to test the drug in mouse models of melanoma and metastatic breast cancer,” Dr. Luo says. “We want to see in what kinds of tumors it might have the best chance to work, whether it causes side effects, and at what dose it’s effective.” The researchers will also continue to explore the biology of SET8 and whether it might be implicated in additional cancers.

Dr. Luo’s research has been funded by the Tri-Institutional Therapeutics Discovery Institute, the Starr Cancer Consortium, and the National Institutes of Health.

ABOUT THE ILLUSTRATION

Many cancers are fueled by chemical changes in histones, the proteins that serve as spools for DNA (histones are pictured in green with cancer-induced changes in red and purple). New drugs that reverse histone changes could convert cancer cells back to normal.
WE’RE CHANGING HOW THE WORLD TREATS CANCER WITH BOLD ADVANCES
IN THE BEGINNING...

...is the embryo and the events that shape the earliest stage of life.

But the expression of the same genes — along with the cell divisions, specializations, and movements that sculpt us into complex multicellular organisms — can also be responsible for cancer. Developmental biologists at Memorial Sloan Kettering work to elucidate the normal behaviors of developing cells that can go awry in the disease and its progression — and the contributions of these researchers are vital to cancer science.
“By understanding how cell types are generated and tissues are formed normally, we can start to tease apart what happens when things are deregulated or aberrant in cancer,” explains Anna-Katerina Hadjantonakis, a member of the Sloan Kettering Institute’s Developmental Biology Program. Dr. Hadjantonakis conducts pioneering research in mice to understand how cells regulate their identity and organize themselves into tissues. For her work in developmental stem cell biology, the mouse is an ideal model. In simple terms, “what’s important in the mouse is likely also important in humans,” she says.

Dr. Hadjantonakis’s special interest is in embryonic stem cells and the critical events that guide early development in the mouse embryo. Her research has allowed her to learn how individual cells evolve their identities during embryonic development.

SEEING IS BELIEVING

Embryonic stem cells are unique, with features that make them especially attractive to scientists. They are pluripotent, meaning that they give rise to all the cells of the fetus and the adult organism; they can be “captured” and maintained indefinitely in culture; and they can be directed to differentiate, or evolve, into various cell types.

A significant distinction of Dr. Hadjantonakis’s research team is their ability to visualize cells individually within a living tissue and to monitor the activities of those cells. One of the key techniques she and her colleagues use is sophisticated live-imaging microscopy, a technology that allows them to observe and track the journey of a single cell in the developing mouse embryo. “We can actually see where the cells are in the embryo, where they travel, what genes they express, and what they do if certain genes are turned on or turned off,” she says.

The technology, developed in Dr. Hadjantonakis’s lab, is the first to allow scientists to visualize individual pluripotent stem cells in live embryos, as opposed to studying them in culture or looking at whole populations of cells in an animal. The cells are labeled with genes that control the expression of what are called fluorescent protein “reporters” that light up in different colors, allowing those cells to be seen and tracked. In whatever process they’re investigating, Dr. Hadjantonakis and her colleagues can then observe the cells involved over a period of time.

In a recent paper in the journal Cell Reports, Dr. Hadjantonakis and her colleagues showed that as cells decide to become pluripotent or differentiated, they rarely — if ever — change their state. This is an important observation, she says, “because pluripotent cells exhibit diversity in stem cell cultures, which seemed to suggest their level of ‘stem-ness’ can change.”

So, she says, “the million-dollar question was whether these fluctuations exist between different developmental states in vivo [in the body].” The answer they’ve uncovered is no. The pluripotent cells studied in mouse embryos in Dr. Hadjantonakis’s lab “never changed their minds — once they decided they were pluripotent, they stayed that way,” she says. In another recent paper in the journal Developmental Cell, her group identified a critical factor promoting a cell’s identity away from pluripotency to an alternative differentiated state.

ILLUMINATING CANCER METASTASIS

In a third recently published paper, in Nature Cell Biology, Dr. Hadjantonakis’s lab looked at a process called gastrulation, an early phase of embryonic development in which pluripotent cells are organized into a three-layered structure known as the gastrula. These three layers, called the ectoderm, mesoderm, and endoderm, are the founding tissues of our bodies.

Again, Dr. Hadjantonakis and her group achieved something that no one else has previously been able to accomplish. “We live-imaged cell identity decisions and morphogenesis [the formation and differentiation of tissues and organs],” she says. “In this instance, we visualized the formation of the endoderm, which is the progenitor of the respiratory and digestive tracts, and associated organs including the liver, pancreas, and thyroid. We found a critical factor that’s involved in instructing cells to become the endoderm.”

What the researchers also discovered is a cell behavior that may be co-opted in cancer metastasis. “We uncovered a cellular and molecular program, or mechanism, for the insertion of cells into an epithelium [the cellular covering of internal and external body surfaces]. We hypothesize that some aspects of this process may be involved in cancer when it spreads from a primary tumor, invading and colonizing distant organs of the body,” Dr. Hadjantonakis says.

“In essence, what we’re doing is deconstructing cancer to its basic building blocks: We need to understand the ‘forward engineering’ in order to unravel what happens in reverse,” she concludes. “There’s great promise in using knowledge gained from the study of developmental biology to help patients with cancer. But to continue developing new, safe, and effective treatments means to continue elucidating the basic defects in the disease. For that, one needs to understand the entire continuum of cell behavior and development — and learning everything we can about when and how cells first become different is paramount. This is what my colleagues and I devote our professional lives to revealing.”
What we’re doing is deconstructing cancer to its basic building blocks. We need to understand the ‘forward engineering’ in order to unravel what happens in reverse.”

– ANNA-KATERINA HADJANTONAKIS
Your T cells are the foot soldiers of your immune system, searching out and destroying invaders they recognize as foreign. Ceaselessly patrolling the body, they’re on the lookout for cellular abnormalities and infections. When they find an intruder, they kill it. They even have the ability to recognize and destroy cancer — although in order to do so with maximum efficiency, they need what you might call close air support.
This support takes the form of the burgeoning field of cancer immunotherapy, which is centered on the idea that a person’s own immune system can be manipulated to fight cancer. Breakthroughs are coming with astonishing rapidity. One of these is ipilimumab (Yervoy™), a drug that’s produced practice-changing results for a number of people with melanoma and works by boosting the body’s natural immune defense against tumors. For certain patients, it shrinks their tumors and significantly prolongs their lives. Memorial Sloan Kettering physicians and scientists played a major role in the development of this therapy.

**THE BATTLE WAGES ON**

Unfortunately, immunotherapy doesn’t help everyone. In fact, in the case of ipilimumab, about 80 percent of people with melanoma get little or no benefit. And thus far, doctors haven’t had a way of predicting which patients are more or less likely to respond to the drug.

MSK scientists now understand more about how ipilimumab works and why it’s able to control melanoma in certain people but not in others. In a report published in 2014 in the New England Journal of Medicine, the researchers showed that the cancer cells of patients who responded to the drug carried a high number of gene mutations — and that some of these mutations were what enabled the immune system to “see” and attack the tumor.

“For the first time, it might be feasible to develop a reliable diagnostic test to help guide treatment decisions by predicting who will respond,” says physician-scientist Timothy Chan, who co-led the study with MSK melanoma expert and immunologist Jedd Wolchok. The finding could also inform new research that may lead to more-powerful immunotherapies for melanoma and other cancers.

**HERE COMES AIR SUPPORT: ACTIVATING A T CELL RESPONSE**

Ipilimumab works by blocking a protein called CTLA-4. Under normal circumstances, CTLA-4 keeps the tumor-fighting activity of the immune system’s T cells in check. But in the presence of ipilimumab, T cells are unleashed and cancer’s ability to evade immune system attack is stripped away. It can now go to work at full force, recognizing and destroying cancer cells.

Recent studies have shown that about one in five patients with metastatic melanoma who are treated with the drug live for more than three years after starting treatment. Before the drug became available, median life expectancy for the disease was seven to eight months.
T CELL, T CELL, WHAT DO YOU SEE?

To gain insight into why some people respond to ipilimumab and others don’t, the researchers collected tumor samples from 64 melanoma patients who had been treated with ipilimumab or tremelimumab, an experimental drug that works in a similar way. About half the tumors came from people who benefited from the treatment and half from people who didn’t.

What investigators discovered was a series of genetic mutations in some of the patients that caused their cancer cells to produce short stretches of protein molecules — called tumor antigens — that make cancerous cells visible to the immune system.

“We found that tumors that had responded to the drug had a higher mutational burden, or overall number of DNA changes,” explains medical oncologist Alexandra Snyder Charen, the study’s first author. “But the correlation isn’t perfect. Not all patients with a high mutational burden in their tumors responded.”

“This made us ask, ‘What is the immune system seeing?’” adds Dr. Wolchok, who played a major role in the development of ipilimumab. “What is it about the mutational landscape of a tumor that helps the immune system recognize and attack it?”

Using sophisticated computational tools, the investigators explored their data and found that the drug-responsive tumors shared a certain type of mutation that makes cancer cells express a new subset of tumor antigens — substances that T cells can detect as foreign to the body. Researchers believe the mutations in these patients’ tumors cause them to express the new antigens, which the immune system then reacts to — and ipilimumab works by enhancing that reactivity.

WHAT’S NEXT?

The study findings could translate into a diagnostic test to detect the mutations in melanoma tumors, the results of which could assist doctors and patients in making more-informed treatment decisions. The MSK team also plans to investigate whether specific tumor mutations influence the effectiveness of other immunotherapy drugs.

“By mapping the mutations that make different types of tumors sensitive to different drugs, we may ultimately be able to offer more patients successful immunotherapy,” Dr. Chan says. “If we know a patient won’t respond to ipilimumab, we may be able to identify other drugs that are more likely to be effective against that person’s tumor.”

This research was supported by Ludwig Cancer Research and grants from the Frederick Adler Fund, the National Institutes of Health, Swim Across America, the Ludwig Trust, Melanoma Research Alliance, Stand Up to Cancer-Cancer Research Institute Immunotherapy Dream Team, Hazen-Polsky Foundation, and the Starr Cancer Consortium. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.
BACTERIA VERSUS BACTERIA

A new approach pits one bacteria against another to fight infection.

Bacteria are the most abundant organisms on Earth and are among the earliest forms of life to have appeared on our planet. One might say that they’re our oldest relatives. Many of us know them only as germs — unpleasant, invisible creatures that can invade our bodies and make us sick. But bacteria are complex and fascinating, coexisting with us all the time and helping us do an array of useful things like make vitamins, break down garbage, and even maintain our atmosphere.
Yes, it’s true: Bacteria do have the power to infect, even to kill. However, Memorial Sloan Kettering researchers have revealed that, when pitted against one another, they may also have the power to heal.

**A GROWING THREAT**

Infection with the bacterial pathogen *Clostridium difficile*, or *C. diff*, is a serious and increasing problem. The Centers for Disease Control calls *C. diff* “an immediate public health threat that requires urgent and aggressive attention.”

*C. diff* infections mostly occur in people who have had recent medical care and antibiotics, often including those who are or have recently been hospitalized. *C. diff* releases toxins that damage the lining of the large intestine, leading to abdominal pain, diarrhea, and sometimes more serious conditions that can take weeks or months to resolve and can — in rare circumstances — lead to death.

Now research from MSK is providing support for a novel preventive strategy that uses a bacterial species naturally found in healthy gastrointestinal tracts to prevent *C. diff* infections.

“It’s been well established that the loss of normal bacteria in the intestines can lead to infection with *C. diff*,” says Eric Pamer, Head of the Division of General Medicine, Chief of MSK’s Infectious Diseases Service, and the senior author of a 2014 study published in *Nature* on the topic. “Now that we know which bacterial species has a protective effect, we can begin to look for ways to develop a clinical treatment.”

**RESTORING THE BALANCE**

For several decades, experts have known that antibiotics can destroy the beneficial bacteria in our guts and allow *C. diff* to flourish. Yet people with *C. diff* infections are usually treated with more antibiotics. The treatment can result in high recurrence rates and persistent colitis, a chronic inflammation of the colon — for which very prolonged antibiotic courses are prescribed.

It would certainly be preferable to treat the infection in a more effective way. But until recently it was unclear which bacterial species provide protection against *C. diff*. Then, clinical studies showed that fecal transplants — in which feces from a healthy donor is introduced into the colon of someone with chronic *C. diff* — can eradicate the infection.

Because it’s impossible to determine all the components and infectious agents in a fecal transplant, doctors have been reluctant to offer the treatment to patients who are immunocompromised. This is especially true of patients undergoing bone marrow transplants (BMTs) or receiving chemotherapy for leukemia or lymphoma.

“The goal of our study was to identify specific bacterial species present in the normal intestinal tract that can be used to prevent or treat *C. diff* infections,” Dr. Pamer says.

**C. SCINDENS TAKES ON C. DIFF**

Charlie Buffie, a graduate student in Dr. Pamer’s laboratory, worked with MSK computational biologists Joao Xavier, Vanni Bucci, and Richard Stein to analyze the DNA sequences of intestinal bacteria obtained from antibiotic-treated lab mice. In doing so, they were able to identify bacterial species that inhibit *C. diff* infection.

In samples from patients undergoing BMTs, they also used computational tools to establish correlations between specific microbes found in the intestines and how susceptible those patients were to *C. diff* infection.

The research team identified a strain found in both mice and humans called *Clostridium scindens* that confers resistance to *C. diff*. When the team gave *C. scindens* to susceptible mice prior to infection with *C. diff*, they found it led to lower levels of the harmful bacterium, which in turn led to a decrease in toxin production and a reduction in colitis.

Before clinical trials in humans can begin, additional research in mice is needed. “One thing we still need to work out is the optimal bacteria companions for *C. scindens,*” Dr. Pamer says. “Our study demonstrates that it’s more effective against *C. diff* if it’s accompanied by three other species. That’s not surprising, because bacteria often work together to support each other in a complex environment like the human intestine.”

This research was funded by the National Institutes of Health and the Tow Foundation.

“Now that we know which bacterial species has a protective effect, we can begin to look for ways to develop a clinical treatment.”

– ERIC PAMER
ERIC PAMER, MD  
Head, Division of General Medicine;  
Chief, Infectious Diseases Service;  
Enid A. Haupt Chair in  
Clinical Investigation

JOAO XAVIER, PhD  
Computational Biologist

Research technician Rebecca Carter works in the laboratory of Eric Pamer.
Scientists get very attached to the tools of their trade. Each object becomes like an old friend — like a car that has seen you through good times and bad. Despite some rust and dings, your affection for it remains undiminished.
“At MSK, we’ve developed more than 30 promising new PET agents. And some are now being used worldwide to translate new drugs into clinical practice.”

– JASON LEWIS

Below left and bottom right

JASON LEWIS, PhD
Chief, Radiochemistry and Imaging Sciences Service; Emily Tow Jackson Chair in Oncology

Below right

WOLFGANG WEBER, MD
Head, Molecular Imaging and Therapy Service
This may in part explain Betsy — or certainly her name. “She” was Memorial Sloan Kettering’s first cyclotron, a particle accelerator used to produce radioactive molecules for medical imaging. MSK was the first hospital in the nation to have this nuclear medicine equipment. Installed in 1967, “she served us faithfully for almost 40 years,” recalls Hedvig Hricak, Chair of MSK’s Department of Radiology. “When old Betsy was finally decommissioned, she was partially held together with duct tape and Krazy Glue!”

You can’t say she wasn’t beloved, but it was finally time to move on. So in 2014, MSK took a leap into the future with the launch of a new cyclotron. This 44,000-pound instrument and the production facility built around it are changing the way our patients are diagnosed and treated by allowing doctors to examine and target tumors with increased precision.

“When the cyclotron, we’re able to fully capitalize on our strength in radiochemistry, nuclear medicine, and molecular imaging to monitor and study cancers in unparalleled detail,” Dr. Hricak says. “It’s advancing the medicine of the 21st century — for patients we are treating today and those we’ll treat in the future.”

A NEW NAME, A NEW FACILITY

The latest cyclotron also has an affectionate moniker: Dorothy, in honor of her namesake, who was swept out of Kansas and into Oz by a tornado.

MSK President and CEO Craig B. Thompson welcomed her at a ceremony in May 2014. He marveled at the tour de force of engineering and logistics required “to actually drop a 20-ton [cyclotron] through the middle of the hospital one weekend” in November and successfully install it in the basement while keeping the hospital fully operational.

“This is truly a cutting-edge facility and one of the largest of its kind in the world,” says radiochemist Jason Lewis, who runs the cyclotron facility and also directs MSK’s Center for Molecular Imaging and Nanotechnology.

“The cyclotron is part of a wide-ranging effort to build the best cancer center in the world in precision-based medicine,” adds Physician-in-Chief and Chief Medical Officer José Baselga. “We have tremendous insights in biology. We have the capacity to produce the best therapies. And now, with this new facility, we’ll have the ability to interrogate tumors and really know what’s going on in individual people’s cancers.”

COUNTING ATOMS

MSK’s cyclotron is now producing the radioactive molecules used in PET imaging. This type of imaging makes it possible to watch biological processes play out in tumors and normal tissues using radioactively labeled imaging agents. “The PET scanner is our molecular microscope,” explains physician-scientist Wolfgang Weber, who heads the Molecular Imaging and Therapy Service. “It allows us to localize molecules in a patient’s body and measure their concentrations with amazing sensitivity. The PET scanner is literally counting individual atoms.”

The technique has multiple uses: It can assess whether a patient will benefit from a drug, monitor a drug’s effectiveness, or study its mechanism of action in a clinical trial. Still other types of PET scans are used to diagnose and stage cancers by measuring tumors’ glucose uptake. PET is also a vital tool for lab studies into the basic biology of cancer.

Radioactive isotopes — the components of PET agents that make molecules visible in the body — are produced in a cyclotron by hitting a nonradioactive molecule with a charged particle flying at extremely high speed, accelerated in a powerful magnetic field.

Hospital cyclotrons produce almost no radioactive waste, and patients who undergo PET imaging are exposed to very low doses of radiation.

DRUG MANUFACTURE

There’s yet another reason Memorial Hospital needed a new cyclotron: Our researchers are creating new medical technologies that require radioactive drugs to be produced and delivered to patients very quickly.

Dr. Lewis points to the manufacture of the isotope carbon-11 as an example. “Carbon-11 can be used to produce hundreds of highly selective PET agents, including some of the best markers available for monitoring prostate cancer and some types of glioma brain tumors,” he says.

But using the isotope poses a challenge due to its short half-life, which is the time it takes for a freshly made batch of the isotope to decay until half of it is gone. Carbon-11’s half-life is all of about 20 minutes.

So while a patient waits in a scanner, Dr. Lewis and his team make the isotope, take it off the cyclotron, couple it with a tracer or drug molecule, sterilize the product, and perform nine or ten different tests to ensure optimal quality and safety. The compound is then propelled to the imaging suite via one of seven pneumatic tubes that connect the cyclotron facility with clinical areas in the hospital. For carbon-11 and a number of other isotopes, the entire process needs to be accomplished within minutes.

“At MSK we’ve developed more than 30 promising new PET agents,” Dr. Lewis notes. “And some are now being used worldwide to translate new drugs into clinical practice.”
“When a patient completes cancer therapy, that shouldn’t be the end of the story,” says Kevin Oeffinger, Director of Memorial Sloan Kettering’s Adult Long-Term Follow-Up Program and the inaugural Director of our new Cancer Survivorship Center.

At MSK, we’ve long understood that the experience of cancer doesn’t end when treatment does. In 2003, we established the Survivorship Initiative — the first of its kind in the country — to coordinate comprehensive services for survivors of adult-onset cancers. And in 2014, the initiative came of age with the creation of this new center.
The goal of survivorship research and patient care is to allow people who’ve had cancer — even multiple times — to live long lives and retain good quality of life through expert surveillance, timely health-preserving interventions, and research into the causes of the long-lasting side effects of treatment.

As the preeminent leader in cancer survivorship, MSK created the Cancer Survivorship Center to bring together already existing initiatives and programs and provide an infrastructure to support cancer survivorship studies. Under the leadership of Dr. Oeffinger and his colleagues, the center seeks to further transform the field as well as formalize standards of care that are already serving as models nationally and internationally.

A HISTORY OF SURVIVORSHIP AT MSK

In 2003, oncology nurse Mary McCabe was recruited from the National Cancer Institute, where she was Deputy Director in the Division of Cancer Treatment and Diagnosis, to lead MSK’s Survivorship Initiative. Today, she serves as Clinical Director of the Cancer Survivorship Center.

When Ms. McCabe joined MSK, there were few clinicians delivering care for cancer survivors or leading studies to better understand the long-term effects — also called late effects — associated with cancer therapy. Eleven years later, nearly 100 MSK clinicians and researchers are involved in this work.

“Survivorship is now a program of consequence at our institution,” she says. “The Survivorship Initiative was established to jump-start the effort, with a strong initial focus on clinical services for patients — but always with an eye firmly fixed on our triple mission as a cancer center. We also wanted to grow our research effort and to focus on education and training.”

Looking even further back, in 1990, MSK’s Department of Pediatrics established the Long-Term Follow-Up Program, one of the earliest such programs in the nation. Led by pediatric endocrinologist Charles Sklar, who has been working in the field since the 1980s, the program helps children and their families navigate and manage the chronic medical conditions often experienced by survivors of pediatric cancers. (Dr. Sklar also serves as Director of Training and Education in the Survivorship Center.)

“Dr. Sklar headed the pioneering effort and developed a wonderful program to monitor the health of these high-risk children and take care of the late effects of their therapy,” says Dr. Oeffinger. “He also led much of the research that helped us understand those risks.”

Dr. Oeffinger’s Adult Long-Term Follow-Up Program provides follow-up care for adults of all ages who were treated for cancer during their childhood, adolescent, or young adult years. “We take over from Dr. Sklar’s program and follow survivors from the age of 18 to, well, age 85-ish or so!” he explains, smiling.

THE CENTER TODAY

Ms. McCabe, Drs. Oeffinger and Sklar, and their colleagues have worked to develop clinical care models for survivors with different risk levels as well as to foster an active research initiative in areas that now include heart health after cancer treatment; cancer recurrence and the development of second cancers; fertility preservation and sexual health; neurocognitive dysfunction; and lifestyle interventions, such as smoking cessation.

“We’re really reaping the rewards of great oncologic care,” says Dr. Oeffinger. “In fact, once they have completed treatment, many patients are at low or moderate risk of cancer recurrence but may have many other healthcare needs. And this is where our survivorship clinics come in: Specially trained nurse practitioners and physician assistants see these patients regularly and offer the comprehensive services that survivors need.” In 2014, MSK had approximately 11,200 patient visits to its nurse practitioner (NP) and physician assistant (PA) cancer survivorship clinics. For high-risk cancer survivors, MSK has physician-nurse practitioner (MD-NP) clinics, which had approximately 1,500 patient visits in 2014.

As patients complete treatment, they transition from the care of their oncologist to an NP or a PA skilled in disease-specific follow-up. For patients with adult-onset cancers, an NP or a PA is embedded within the clinical team so patients do not need to leave their oncology physician.

“The value of having an NP or a PA as part of the team is twofold,” Ms. McCabe explains. “First, team members do not have to ‘give up’ the patients they have been treating and who are doing well, and that gives them a great deal of personal satisfaction. And, for the patients, they don’t have to leave the team that has treated them.”

The first clinics based on the NP model began in 2006 for lymphoma, thoracic surgery, and prostate surgery patients. Currently, MSK provides follow-up care for survivors of breast, cervical, colorectal, endometrial, esophageal, head and neck, kidney, lung, ovarian, prostate, and thyroid cancers and melanoma, as well as for those who have undergone blood and marrow stem cell transplantation.

All patients seen in the NP and the MD-NP clinics are given a cancer treatment summary and survivorship care plan, a blueprint for navigating post-treatment life and a communication tool for their primary care physician.
The goal of survivorship care and research is to allow people who have had cancer to live long lives and retain good quality of life through surveillance, health-preserving interventions, and research into the causes of the side effects of treatment.

TO PREVENT AND TO TREAT

Although much is known about cancer survivorship, a great deal remains to be learned. The aim of research is to assess the long-term impact of cancer and its treatment in order to allow clinicians to intervene and minimize or prevent the late effects of therapy.

Physician-scientists from across MSK are conducting numerous ongoing investigations in these areas. This research includes how best to detect early signs of heart disease in survivors of Hodgkin’s lymphoma — a result of radiation to the chest and the chemotherapy used in treatment — and studies being done by behavioral psychologist Tim Ahles that focus on how to treat or prevent the cognitive changes associated with chemotherapy for breast cancer. (Dr. Ahles is Co-Director of Research in the Survivorship Center.)

“We’re also doing exciting studies investigating the effects and underlying mechanisms of how targeted, individualized exercise training might prevent tumor progression and metastasis and alter response to cancer therapies, as well as treat late effects,” Dr. Oeffinger says. (Exercise scientist Lee Jones, who co-directs research in the Survivorship Center with Dr. Ahles, is leading that area of research. To learn more about his work, see page 38. Surgical oncologist Larissa Temple serves as the Survivorship Center’s Director of Clinical Care.)

THE NEXT DECADE

Beyond the institution, MSK clinicians are collaborating with colleagues around the United States and the world.

“We’ve gone from being an initiative in 2003 to a center that today is truly transinstitutional and transdisciplinary,” says Dr. Oeffinger. “Our goal now is to seed and to fertilize — and then to support growth across all areas and at all levels.”

“We have a tremendous opportunity to develop and evaluate our clinical programs in a way that not only contributes to the care that our survivors receive but also helps determine standards for how oncology care is provided in the future,” Ms. McCabe adds. “We’ve worked hard to achieve a certain set of goals during this first decade and have identified a very ambitious set of goals for the next ten years. It’s an exciting time to be at Memorial Sloan Kettering and to be doing this work.”

---

Left to right
MARY McCABE, RN, MN
Clinical Director,
Cancer Survivorship Center
KEVIN OEFFINGER, MD
Director, Adult Long-Term Follow-Up Program
CHARLES SKLAR, MD
Director, Long-Term Follow-Up Program
A FIELD IN MOTION:
FIGHTING CANCER
WITH EXERCISE

A Conversation
with Exercise Scientist
Lee Jones
Exercise as a treatment for cancer? Sound too good to be true? It may not be. Exercise scientist Lee Jones, Director of the Cardio-Oncology Research Program (CORP) at Memorial Sloan Kettering, is devoted to teasing out the answer to this and other questions. Using an approach that spans basic and clinical science, his team designs and tests the effects of individually prescribed exercise training to prevent or minimize the adverse cardiovascular side effects of cancer therapy. They’re also working to answer this potentially paradigm-shifting question: Can exercise be an effective treatment for cancer itself? Here, Dr. Jones talks about some of this work.

CAN YOU TELL US A LITTLE ABOUT THE RELATIONSHIP BETWEEN EXERCISE AND DISEASE?

If you look at the role of exercise in noncancer chronic diseases such as heart disease or heart failure and type 2 diabetes, exercise is typically part of the standard of care. In fact, exercise is the central piece of treatment for a lot of these diseases. So for example, somebody who’s had a heart attack is referred to cardiac rehabilitation, in which exercise therapy is the primary component and everything else is built around it.

An exercise prescription is also one of the front-line therapies for the prevention of many diseases. If you go to your primary care physician and you’re at risk for one of the most common chronic diseases such as diabetes or cardiovascular disease, one of the first things he or she will talk to you about is lifestyle interventions, whether that’s stopping smoking, modifying your diet, or losing weight — and the conversation always, or should always, include participation in a regular exercise program. For cancer, there’s convincing evidence that regular exercise is associated with a significant reduction in the risk of certain types such as breast, colon, and prostate cancer.

SO WHAT DO WE KNOW — AND NOT KNOW — ABOUT THE ROLE OF EXERCISE IN CANCER?

While we’ve recognized the critical importance of exercise therapy for the prevention and treatment of other diseases for decades, the value of exercise in people with cancer was left largely untouched until recently. The prevailing view was that cancer is associated with poor outcomes, and that patients who either are undergoing or have finished intensive cancer treatments would not be able to participate in or tolerate structured exercise training. Because of this, many patients were — and may still be — advised to rest and avoid strenuous exercise, particularly during treatment.

However, things are now changing radically for a number of reasons. Perhaps the most important is the enormous progress we’ve made in cancer screening and prevention as well as treatment. In combination, this now means that people are living longer than ever before after a cancer diagnosis, and that accordingly, certain cancer diagnoses are no longer considered a death sentence. Today, with nearly 14 million people in the United States living with a history of cancer, exercise has gained a lot of traction as part of the survivorship movement.
CANCER CAN BE PREVENTED. IT CAN BE DETECTED EARLY. AND IT CAN BE TREATED. IT'S A IMPOSSIBILITY. BUT PARADOXICALLY, IMPROVEMENTS IN THERAPY FOR CANCER HAVE GIVEN PEOPLE SUFFICIENT LIFE SPANS TO PUT THEM AT RISK FOR SUFFERING THE [LATE] EFFECTS OF THERAPY, SOMETIMES YEARS AFTER THAT THERAPY IS OVER.

As part of their treatment, patients can receive a cocktail of different therapies—surgery, radiation, chemotherapy. We’re finding that these treatments, while effective at controlling the growth and progression of cancer cells, also cause damage to the components of the cardiovascular system, especially the heart, as well as the skeletal muscle. Together, this leads to a dramatic decrease in patients’ ability to exercise and even perform normal activities of daily living.

What we’ve learned is that cancer therapy leads to a reduction in a patient’s cardiovascular reserve capacity—commonly known as your fitness level—and it appears to stay impaired even years after therapy. In fact, we’ve found that even a short course of chemotherapy has the same impact on the cardiovascular system as ten years of normal aging. But the good news is that in our clinical trials, we’re discovering that these effects can be attenuated in individuals who participate in structured exercise training prescriptions.

Our second major focus is understanding and harnessing the potent therapeutic properties of exercise as a form of cancer treatment to prevent recurrence and even help conventional or novel cancer drug therapies work more effectively. We want to discover if and how exercise impacts tumor biology, both in the early and advanced stages of disease.

We’re actually trying to approach the development and investigation of exercise treatment as you’d think about the development of a new drug. The drug we’re testing just happens to be called exercise, but I believe that the way we test it should be no different. In our program, we are trying to adopt, whenever possible, the same type of sequential study steps with similar types of endpoints that oncologists and cancer biologists use in the development of new targeted therapies—we think of it as precision exercise treatment.

IS THERE A PROJECT THAT STANDS OUT AS AN EXAMPLE OF THIS APPROACH?

Here’s a good example: We’re interested in testing the efficacy of exercise across the entire cancer trajectory, from prevention to advanced disease. To this end, we’re about to launch a study looking at the earliest stages of cancer development. When we see patients in the clinic—after they’ve been diagnosed—a lot of the very early events in the development of the disease have already occurred. I want to look at how exercise might be affecting some of these.

To do this, we’re going to perform a randomized controlled trial in women diagnosed with atypia [abnormal changes within the breast tissue]. These changes put them at significantly higher risk of developing invasive breast cancer. A total of 100 women will be assigned to a low, medium, or high dose of six months of supervised aerobic training [treadmill walking]—low being 75 minutes a week, medium being 150, high being 300 minutes. The fourth arm, the control group, will be women who will receive the usual standard of care [with no additional prescription for exercise]. All our aerobic training sessions are individualized to participants based on their fitness levels, which we measure at the beginning of the program using a sophisticated exercise stress test.

Before randomization, all women will undergo a battery of assessments including a core biopsy of the normal breast tissue. After six months, the biopsy will be repeated and we’ll be able to evaluate, for the first time, whether aerobic training lowers the expression of genes in the normal breast tissue that are known to promote breast cancer, and the optimal dose of exercise to stimulate these changes. What’s also unique about this study is that we’ll be performing a study in mice that is the mirror image of the human clinical trial, known as a co-clinical trial. Using this approach, we’ll be able to learn things in the mouse study that will inform analyses in the human trial. To my knowledge, this is the first study ever to adopt this approach in clinical exercise science in any chronic condition.

Similarly, we’re going to be starting a randomized clinical trial in men with early-stage prostate cancer who are part of MSK’s active surveillance program. In this approach, treatments such as surgery or radiation therapy are deferred because tests show that the tumor is currently not life threatening or is at low risk of progressing. Our trial is going to test the effect of 24 weeks of supervised aerobic exercise versus the usual care on the prostate microenvironment [the cellular environment in which a tumor exists] and cancer-related anxiety among these men. Again, to my knowledge, this will be the first trial to study the effects of exercise on changes in the tumor itself.

Findings from both these studies will provide unique insights into the effects of exercise on tumor and tissue biology as well as the biologic mechanisms underpinning these effects. This will help us design future studies as well as optimize the efficacy of exercise.

Findings from both these studies will provide unique insights into the effects of exercise on tumor and tissue biology as well as the biologic mechanisms underpinning these effects. This will help us design future studies as well as optimize the efficacy of exercise.
YOU'RE ALSO INTERESTED IN CANCER RECURRENTCE AND METASTATIC DISEASE AND THE POTENTIAL IMPACT OF EXERCISE IN THESE CIRCUMSTANCES.

I am. I’m very interested in prevention of recurrence and even the role of exercise in individuals with advanced disease. We’re starting to explore if and how exercise might affect the course of disease in these populations.

In terms of metastasis, I think exercise not only changes things like the breast tissue but also alters the microenvironments in tissues such as the lung and bone marrow – those places in the body where metastatic cancer cells may be dormant. I believe exercise may be able to actually change the microenvironment of such tissues to keep metastatic cancer cells asleep for longer – and perhaps even permanently. This is an area we’re studying collaboratively with various colleagues at MSK.

YOUR WORK SPANS BOTH LABORATORY AND CLINICAL RESEARCH.

It does. Along with clinical studies in patients, we’re also starting to build a robust laboratory research program. Among the things we’re doing is working with mouse models as well as zebrafish [in collaboration with physician-scientist Richard White’s laboratory in the Sloan Kettering Institute] to study what’s going on at the molecular level to better elucidate the effects and underlying mechanisms of exercise training on cancer initiation and progression.

YOU JOINED MSK IN FEBRUARY 2014 AND SO ARE RELATIVELY NEW TO THE INSTITUTION. CAN YOU TELL US HOW YOU FEEL ABOUT YOUR EXPERIENCE SO FAR?

My expectations have already been far exceeded. Across the board — from oncologists to the clinical trials office and various administrative bodies — the support has been nothing short of incredible. I came to MSK because our program goal is to make precision exercise treatment part of the standard of care for people with or at risk of cancer. To accomplish this, we need to do the best science and build a convincing evidence base, and that requires that we be at the best cancer center. MSK is that place!
30 Years of Changing How the World Treats Cancer

A Talk with John Gunn
In March 2015, John R. Gunn retired as Memorial Sloan Kettering’s Executive Vice President and Chief Operating Officer. Mr. Gunn joined MSK in 1982 as Vice President of Finance and was a principal MSK leader and a confidant to three successive presidents throughout his long and distinguished service.

Mr. Gunn guided MSK’s physical growth beyond the “superblock” at 1275 York Avenue in ways that have set the standard around the country. Starting with the Rockefeller Research Laboratories building (opened in 1989) and the Rockefeller Outpatient Pavilion (opened in the 1990s), and continuing through the current development of the Josie Robertson Surgery Center, he led the transformation of cancer care delivery in the ambulatory setting. With projects that spanned two decades, Mr. Gunn spearheaded efforts that created space to accommodate 21 new operating rooms, state-of-the-art pathology laboratories, and a new family-friendly Pediatric Day Hospital, all without disruption to MSK’s ongoing patient-care activities.

The Mortimer B. Zuckerman Research Center, to which Mr. Gunn made significant and creative contributions, has allowed MSK scientists to explore the critical questions of cancer biology and to speed the translation of their discoveries into effective therapies. More recently, he provided leadership during the complex approval process for MSK’s planned outpatient center on East 74th Street.

Here, he talks with us about the past 30 years in his own life and the life of MSK, and discusses his contributions to changing the way the world treats cancer.
YOU WERE BORN IN BRITAIN AND EDUCATED IN LONDON. WHY DID YOU COME TO THE UNITED STATES?

As a kid, when I was 11 or 12, I used to go into WH Smith, the newspaper and magazine seller in England. And I bought the *Saturday Evening Post* every week because it serialized stories. I also loved to look at the ads — at the cars and things like that. I promised myself that one day if I ever got the opportunity, I was going to see what the United States was like.

WHEN DID THE OPPORTUNITY PRESENT ITSELF?

In 1969, during the Vietnam War. A lot of young men had been drafted and it was difficult to find young qualified accountants in the United States. I was a chartered accountant in London, and Medicare was just starting. Blue Cross/Blue Shield of Chicago — who had a contract to do the audits — was looking for auditors. So the “Chicago Blues,” as they were known, came to London, recruited about 35 qualified accountants, and flew us over for this one-year project. I decided I should get a green card — which was easy to do back then — in case I liked it here.

During that year, I met some folks at Arthur Andersen, which was the big accounting firm in Chicago, and they asked if I’d like to work for them. I accepted their offer. One of my clients was Michael Reese Medical Center, which was going through fiscal problems. Eventually I got an offer to work in finance at Michael Reese. [Mr. Gunn stayed with Michael Reese from 1974 to 1982, rising to become Vice President of Finance.]

YOU JOINED MSK IN 1982 AS VICE PRESIDENT OF FINANCE. WHEN YOU ARRIVED, WHAT WAS THE BIGGEST CHALLENGE YOU FACED?

I was originally recruited for the purpose of fixing MSK’s accounts receivable. It was a pretty sloppy billing system. At the time, outpatient cancer care was a new activity for MSK, so we were barely collecting any money for our outpatient services. Inpatient was a little more straightforward. Physician billing was also a mess because a lot of it was done by the doctors themselves and some of it was done centrally. Simply put, everyone was doing their own thing.

My role was to try to pull it all together. It was a big issue with the Board. The then-chairman of the Audit Committee was John Reed, who later went on to run Citibank. His feeling was that if we couldn’t run this basic billing operation, how could we run the rest of the place? He worked very closely with me and my colleagues until we got it pretty well fixed.
YOU WERE ALSO DEEPLY INVOLVED IN WORKING TO EXPAND PATIENT ACCESS TO MSK.

Yes. Anecdotally, shortly after I came to MSK, I bought a place in upstate New York. I’ll always remember the broker saying, “God forbid anyone I know gets cancer — at least now I know someone at Memorial who’ll be able to get us in.”

I thought, How odd. Why would you need to know somebody to “get in”? But that was the perception at the time: that in order to become a patient at MSK, you needed to know somebody. I wanted to change that.

In the intervening years we’ve worked hard to overcome both the problem and the perception. We’ve definitely made progress with our Physician Access Service, our network of suburban locations, our various community outreach activities — but there’s still work to be done to continue to expand access and to let people know that we’re not a closed system.

IN THE EARLY YEARS OF YOUR TENURE, MSK WAS PRIMARILY DELIVERING CARE IN A HOSPITAL SETTING. HOW DID YOU BEGIN TO CHANGE THAT?

Except for pediatrics — they’d developed the Pediatric Day Hospital before I got here — you’re right that MSK was mostly delivering care on an inpatient basis. So in the early to mid-1980s we started a big test to see if giving patients chemotherapy as outpatients made more sense than admitting them for a three-day hospital stay. The results proved conclusively that we had much happier patients because they got to go home. It was also safe, and it was a much less expensive way to deliver care.

Historically, if you look at MSK’s revenue streams, back then it was about 60 or 70 percent inpatient, 20 percent outpatient, perhaps 10 percent doctors. Today, it’s completely flip-flopped: It’s about 70 percent outpatient, 20 percent doctors, and approximately 10 percent inpatient.

THE LAURANCE S. ROCKEFELLER OUTPATIENT PAVILION — KNOWN FAMILIARLY IN THE HALLS OF MSK AS 53RD STREET — WAS A BIG STEP IN THE FUTURE OF OUTPATIENT CANCER CARE.

True. But even before then we’d already renovated existing floors of the Enid A. Haupt Pavilion in the hospital for ambulatory care. By the 1990s, we’d outgrown those floors and we created the Evelyn H. Lauder Breast Center on East 64th Street.

Then in 1999 came the Rockefeller Outpatient Pavilion. And after that, the Sidney Kimmel Center for Prostate and Urologic Cancers on East 68th Street. And we’re still growing. In 2009, we opened the MSK Breast and Imaging Center [which houses the Evelyn H. Lauder Breast Center], and this year we created yet another new outpatient facility on East 60th Street.

Next year, MSK will open the Josie Robertson Surgery Center to accommodate more ambulatory surgeries. [See more about the JRSC on page 57]

A little side note: The 53rd Street building was the only facility Laurance ever agreed to have named after him.

OUR NETWORK OF SUBURBAN LOCATIONS HAS BEEN EXTREMELY IMPORTANT IN INCREASING PATIENT ACCESS TO MSK CARE.

Absolutely. They’re a critically important piece of our overall cancer care delivery system. They were designed so that we could extend the highest standards of comprehensive cancer care — and the unparalleled expertise of our staff — to more patients within a unified system.

And we’re continuing to expand our ability to treat patients in their own communities, both in terms of facility size and the geographic areas we cover. In 2014, we opened MSK West Harrison to serve residents of the Hudson Valley, and in 2016 we’ll open MSK Monmouth, for people who live on the Jersey Shore and beyond.

CAN YOU TALK A BIT ABOUT HOW THE NEW MSK CANCER ALLIANCE CAME ABOUT? YOU WERE VERY INVOLVED IN THAT PROCESS.

Sure. There are two ways to go with the affiliation agreements. You can say, “Give us a million dollars and you can use our name.” That’s easy. But most of us at MSK think our name is probably our biggest single asset. You know, it’s one of the probably five or six name brands in American medicine that’s known across the country.

In typical MSK fashion, we took a possible affiliation very seriously and asked, “How can we truly improve cancer care in the community at a distance?” And that required us to make sure that our partner or the affiliate we chose was willing to come and be measured at the bar, so to speak.

And Hartford HealthCare [the first partner in the MSK Cancer Alliance] turned out to be that kind of a place. They took it very seriously and worked with us for almost a year before they got their certification. That required seeing what kind of cancer care they delivered, seeing where we thought it was lacking or where it was acceptable, getting them on a remedial plan to correct what they were doing up to a standard that we felt comfortable with, and then making them an affiliate.

Now, what’s really in it for us? Access to a lot more patients. Because in doing clinical research today you need large cadres of patients, many more than we would treat as an individual institution. So one of the things driving the affiliation was how we would be able to do that. In the end, high-quality research yields better outcomes for patients. So far — touch wood — it’s working out terrifically. Hartford HealthCare patients will be enrolled in MSK clinical trials that would otherwise have been unavailable to them.
YOU’VE WORKED WITH THREE MSK PRESIDENTS: PAUL MARKS, HAROLD VARMUS, AND NOW CRAIG THOMPSON. THESE ARE THREE VERY DIFFERENT MEN WITH VERY DIFFERENT STYLES. HOW HAVE YOU MANAGED IT?

I honestly don’t think I’ve done many things that differently from president to president. I certainly spent a lot of time with each man and I probably helped grease a few wheels and soothe some ruffled feathers. Change is never easy — there will always be squeaky wheels and ruffled feathers. It may have also been useful that I have a fairly calm personality — my feathers aren’t easily ruffled!

HOW HAVE YOU SEEN YOUR ROLE OVER MORE THAN 30 YEARS AT MSK?

There have been so many areas in which I’ve been involved over the years, but I’d say in an overarching sense my role has been to help our staff to get on and do well at their jobs. It’s been to make sure that the voices of all our constituencies are heard and that we act according to their needs and concerns. This includes our patients, our doctors, our nurses, and our scientists.

I used to be involved in recruiting and, in particular, in actually getting people here. Moving to New York is a big deal. And if you’re paying someone a salary and want them to settle in quickly and get on with what they’ve been hired to do, well, you don’t want them worrying about the cost of a roll of paper towels at Gristedes! For those coming from overseas it’s even a bigger shock to the system. So to the extent that I’ve been able to help with that, I have.

One of my ideas that I believe has worked out well has been our employee orientation program, in which all new employees are required to participate before officially joining the MSK family. It came about when my wife and I went down to Disney World to Disney School, where they talked about how to take care of people in Disney World. Every one of their employees went through the orientation, and they were taught that the most important person they’d be dealing with is the customer. And that’s what we tell people in orientation here: No matter what you do, the way you do it can have a positive or a negative effect on somebody with cancer — whether you’re in research or are a security guard. It matters at all levels.

And one of the things I’m pleased about are the letters I’ve gotten over the years in which people say, “This was the most unique hospital I’ve ever been in anywhere in the world. Everybody was so nice — whether it was the lady delivering the food, or the woman coming in to sweep the floors, or the radiation oncology technician, or the nurse who really went out of her way to be helpful.”

“From the time John joined us, we’ve been blessed to have had a leader with the wisdom, skill, and imagination to make extraordinary things happen. There are few lives at MSK that he hasn’t touched, including the hundreds of thousands of patients and families who have passed through our doors in the time he’s been with us. He’s guided our institution through good times and bad and has always asked the question — no matter what the issue, no matter how knotty the problem — ‘How can we make this work? How can we make it happen?’ And he has constantly strived to do what is good, and true, and right. John Gunn is a remarkable man. A brilliant, courageous leader. A generous collaborator. And a true friend.”

– DOUGLAS A. WARNER III
Chairman
Boards of Overseers and Managers
YOU’VE CLEARLY MOVED OUTSIDE THE PARAMETERS OF YOUR JOB TITLE!

I’ve taken on lots of responsibilities over the years to make sure things keep rolling. It’s the old make-the-trains-run-on-time syndrome. But it’s what I like best: thinking about the future, thinking about how we’re going to stay on top. I enjoy challenges of all sorts.

LOOKING BACK, CAN YOU POINT TO A FEW THINGS THAT YOU’RE MOST PROUD OF?

I’m very proud of the fact that we were probably one of the first places in the country to go big into ambulatory chemotherapy because I believe it was good for our patients. I’m proud of 53rd Street, which was way ahead of its time and for which my wife, Clarice [Albright], gets much of the credit. [Ms. Albright was MSK’s Hospital Administrator at the time.] She was instrumental in the physical design and I think it still holds up and works well to this day.

I’m proud of the Brooklyn Infusion Center because, again, we designed it around patient comfort and convenience.

And the deal with Amgen was pretty special! [In the 1970s, MSK researchers isolated a naturally occurring protein called granulocyte colony stimulating factor, or G-CSF, that can stimulate bone marrow to produce more neutrophils, a type of white blood cell that fights off infections. The team then demonstrated that filgrastim — which is closely related to G-CSF — can be used to speed up the body’s renewal of neutrophils after chemotherapy. Since 1991, filgrastim has been marketed by Amgen as Neupogen®.] That license agreement, which has produced hundreds of millions of dollars over the more than 20 years we’ve had it, has been a big source of support for our research operations. [The agreement is scheduled to end in 2017.]

DO YOU THINK BEING BRITISH HAS HELPED YOU?

I do think that in New York it helps to sound British — people pay more attention to you! I also think that common sense and fair play have always been characteristics of good British administration. My management style has been to empower people — to set goals and then give people a long leash. Naturally, I believe in hiring good people and I carefully monitor progress, but it’s all with the objective of seeing how we can continue to improve our services.

I’ve always encouraged people to take risks and I’ve wanted them to succeed with new ideas because it’s the new ways of doing things that keep you ahead of the game.

ANY FINAL THOUGHTS FOR US?

There’s an enormous responsibility we have at this institution. First and foremost, it involves being supportive of every single patient. Our patients trust us. Their families trust us. We can’t let them down. I have been conscious of that every moment of every day I’ve been here. I’m not able to walk away from problems. I want to fix them.

I’m leaving MSK in the excellent and capable hands of Kathryn Martin, who will succeed me as COO. I’ve worked with Kathryn since 1999 in her role as Hospital Administrator and, more recently, as Senior Vice President and Hospital Administrator. She’s led the hospital alongside Physicians-in-Chief David Golde, Bob Wittes, and José Baselga with vision, creativity, and intelligence.

I also want to mention Michael Gutnick, MSK’s Executive Vice President and Chief Financial Officer. During the many years we’ve worked together, Mike has played a vital role in helping to maintain the financial stability of MSK — and he’ll continue to do so with outstanding skill.

I’ll miss my colleagues and my friends here, although I’ll keep in touch and will follow MSK as it moves into the future. I am much more proud of this place than I am of myself. This is a very unique organization with a great Board, a superb management team, and wonderful people.

I sometimes joke that this is such an extraordinarily strong organization that it’s managed to be successful despite me in my role and the three presidents we’ve had to date [Mr. Gunn says with a big, dry smile]!

“...When I think of John Gunn, I think of guidance, inspiration, and creativity. I think of his focus on providing patients with the most advanced, comprehensive, and humane cancer care available. I also think of his equally tireless efforts in championing the programs and facilities that have made possible the research that contributes to that care. John has been one of the chief visionaries behind MSK’s expansion plans, both clinical and scientific. He understood our past and our future, and his vision has had a profound and lasting impact on this institution.”

— CRAIG B. THOMPSON
President and CEO
## PATIENT CARE

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient Admissions: Adults</strong></td>
<td>22,852</td>
<td>22,983</td>
<td>23,139</td>
<td>20,773</td>
<td>20,640</td>
</tr>
<tr>
<td><strong>Patient Admissions: Children</strong></td>
<td>1,494</td>
<td>1,503</td>
<td>1,459</td>
<td>1,553</td>
<td>1,504</td>
</tr>
<tr>
<td><strong>Total Admissions</strong></td>
<td>24,346</td>
<td>24,486</td>
<td>24,598</td>
<td>22,326</td>
<td>22,144</td>
</tr>
<tr>
<td><strong>Total Patient Days</strong></td>
<td>143,532</td>
<td>140,990</td>
<td>149,368</td>
<td>144,345</td>
<td>146,855</td>
</tr>
<tr>
<td><strong>Average Patient Stay (days)</strong></td>
<td>5.9</td>
<td>5.8</td>
<td>6.1</td>
<td>6.5</td>
<td>6.6</td>
</tr>
<tr>
<td><strong>Bed Occupancy Rate</strong></td>
<td>83.7%</td>
<td>82.2%</td>
<td>87.0%</td>
<td>83.0%</td>
<td>84.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Outpatient MD Visits: Manhattan</strong></td>
<td>418,415</td>
<td>432,802</td>
<td>436,510</td>
<td>463,724</td>
<td>480,260</td>
</tr>
<tr>
<td><strong>Outpatient MD Visits: Regional Network</strong></td>
<td>97,658</td>
<td>103,098</td>
<td>104,964</td>
<td>108,198</td>
<td>113,699</td>
</tr>
<tr>
<td><strong>Total Outpatient Visits</strong></td>
<td>516,073</td>
<td>535,900</td>
<td>541,474</td>
<td>571,922</td>
<td>593,959</td>
</tr>
<tr>
<td><strong>Screening Visits</strong></td>
<td>23,373</td>
<td>20,518</td>
<td>15,519</td>
<td>12,826</td>
<td>10,282</td>
</tr>
<tr>
<td><strong>Surgical Cases</strong></td>
<td>19,362</td>
<td>19,374</td>
<td>19,691</td>
<td>20,465</td>
<td>20,420</td>
</tr>
<tr>
<td><strong>Radiation Treatments and Implants: Manhattan</strong></td>
<td>59,223</td>
<td>60,393</td>
<td>60,289</td>
<td>61,335</td>
<td>62,375</td>
</tr>
<tr>
<td><strong>Radiation Treatments and Implants: Network</strong></td>
<td>47,926</td>
<td>51,615</td>
<td>50,476</td>
<td>53,660</td>
<td>55,229</td>
</tr>
<tr>
<td><strong>Total Radiation Treatments and Implants</strong></td>
<td>107,149</td>
<td>112,008</td>
<td>110,765</td>
<td>114,995</td>
<td>117,604</td>
</tr>
<tr>
<td><strong>Diagnostic and Interventional Radiology Procedures</strong></td>
<td>362,609</td>
<td>377,360</td>
<td>391,187</td>
<td>416,360</td>
<td>435,501</td>
</tr>
<tr>
<td><strong>Clinical Investigation Protocols</strong> (excludes studies closed to accrual)</td>
<td>552</td>
<td>552</td>
<td>657</td>
<td>735</td>
<td>776</td>
</tr>
</tbody>
</table>
### STAFF

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sloan Kettering Institute Members</td>
<td>142</td>
<td>143</td>
<td>146</td>
<td>143</td>
<td>140</td>
</tr>
<tr>
<td>Hospital Attending Staff</td>
<td>804</td>
<td>834</td>
<td>876</td>
<td>935</td>
<td>995</td>
</tr>
<tr>
<td>Registered Nurses</td>
<td>1,945</td>
<td>2,018</td>
<td>2,133</td>
<td>2,221</td>
<td>2,373</td>
</tr>
<tr>
<td>Administrative and Support Staff</td>
<td>8,613</td>
<td>8,989</td>
<td>9,281</td>
<td>9,707</td>
<td>10,223</td>
</tr>
<tr>
<td><strong>Total Staff</strong></td>
<td>11,469</td>
<td>11,950</td>
<td>12,402</td>
<td>12,975</td>
<td>13,699</td>
</tr>
<tr>
<td>Volunteers</td>
<td>942</td>
<td>1,058</td>
<td>1,018</td>
<td>1,004</td>
<td>902</td>
</tr>
</tbody>
</table>

*In 2014, 32 staff members held appointments in both the Institute and the Hospital.

### EDUCATION

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residents and Clinical Fellows — Positions</td>
<td>447</td>
<td>440</td>
<td>445</td>
<td>464</td>
<td>465</td>
</tr>
<tr>
<td>Residents and Clinical Fellows — Annual Total</td>
<td>1,625</td>
<td>1,676</td>
<td>1,682</td>
<td>1,691</td>
<td>1,674</td>
</tr>
<tr>
<td>Research Fellows</td>
<td>295</td>
<td>321</td>
<td>320</td>
<td>323</td>
<td>351</td>
</tr>
<tr>
<td>Research Scholars</td>
<td>132</td>
<td>131</td>
<td>124</td>
<td>133</td>
<td>110</td>
</tr>
<tr>
<td>Research Associates</td>
<td>94</td>
<td>82</td>
<td>89</td>
<td>91</td>
<td>95</td>
</tr>
<tr>
<td>Graduate Research Assistants</td>
<td>23</td>
<td>29</td>
<td>39</td>
<td>41</td>
<td>47</td>
</tr>
<tr>
<td>PhD Candidates</td>
<td>231</td>
<td>225</td>
<td>222</td>
<td>227</td>
<td>239</td>
</tr>
<tr>
<td>MD/PhD Candidates</td>
<td>26</td>
<td>21</td>
<td>21</td>
<td>19</td>
<td>18</td>
</tr>
<tr>
<td>Registrants in CME Programs</td>
<td>2,554</td>
<td>2,333</td>
<td>3,968</td>
<td>3,681</td>
<td>5,614</td>
</tr>
<tr>
<td>Medical Observers</td>
<td>541</td>
<td>526</td>
<td>566</td>
<td>630</td>
<td>579</td>
</tr>
<tr>
<td>Medical Students</td>
<td>391</td>
<td>419</td>
<td>431</td>
<td>392</td>
<td>505</td>
</tr>
<tr>
<td>Nursing Students</td>
<td>105</td>
<td>142</td>
<td>178</td>
<td>179</td>
<td>257</td>
</tr>
<tr>
<td>Social Work Students</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Radiation Oncology Technology Students</td>
<td>14</td>
<td>14</td>
<td>13</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Physical Therapy Students</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Occupational Therapy Students</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>
FINANCIAL SUMMARY

(in thousands)

2014 TOTAL OPERATING REVENUE
$3,303,111

- $2,560,457 Patient Care Revenue
- $229,562 Grants and Contracts
- $183,937 Contributions Allocated to Operations
- $162,710 Royalty Income
- $87,917 Investment Return Allocated to Operations
- $15,885 Transfer of Board-Designated Annual Royalty Annuitization
- $62,643 Other Income

2014 TOTAL OPERATING EXPENSES
$3,088,799

- $1,782,477 Compensation and Fringe Benefits
- $1,062,601 Purchased Supplies and Services
- $217,342 Depreciation and Amortization
- $50,147 Interest Expense
- $35,859 Provision for Bad Debts and Assessments
- ($59,627) Less Fund-Raising Expenses Transferred to Non-Operating Income (Expenses)
### OPERATING REVENUES (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care Revenue</td>
<td>$1,854,776</td>
<td>2,141,421</td>
<td>2,201,941</td>
<td>2,367,731</td>
<td>2,560,457</td>
</tr>
<tr>
<td>Grants and Contracts</td>
<td>186,327</td>
<td>190,948</td>
<td>185,160</td>
<td>202,061</td>
<td>229,562</td>
</tr>
<tr>
<td>Contributions Allocated to Operations</td>
<td>117,323</td>
<td>130,791</td>
<td>144,497</td>
<td>164,943</td>
<td>183,937</td>
</tr>
<tr>
<td>Royalty Income</td>
<td>68,663</td>
<td>77,510</td>
<td>78,350</td>
<td>94,058</td>
<td>162,710</td>
</tr>
<tr>
<td>Other Income</td>
<td>44,874</td>
<td>48,351</td>
<td>51,167</td>
<td>57,150</td>
<td>62,643</td>
</tr>
<tr>
<td>Investment Return Allocated to Operations</td>
<td>100,389</td>
<td>104,699</td>
<td>75,877</td>
<td>82,028</td>
<td>87,917</td>
</tr>
<tr>
<td>Transfer of Board-Designated Annual Royalty Annuity</td>
<td>41,578</td>
<td>46,417</td>
<td>51,709</td>
<td>57,495</td>
<td>15,885</td>
</tr>
<tr>
<td><strong>Total Operating Revenues</strong></td>
<td>$2,413,930</td>
<td>2,740,137</td>
<td>2,788,701</td>
<td>3,025,466</td>
<td>3,303,111</td>
</tr>
</tbody>
</table>

### OPERATING EXPENSES (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compensation and Fringe Benefits</td>
<td>$1,361,032</td>
<td>1,466,667</td>
<td>1,582,212</td>
<td>1,689,501</td>
<td>1,782,477</td>
</tr>
<tr>
<td>Purchased Supplies and Services</td>
<td>772,968</td>
<td>835,621</td>
<td>879,219</td>
<td>924,691</td>
<td>1,062,601</td>
</tr>
<tr>
<td>Provision for Bad Debts and Assessments</td>
<td>11,046</td>
<td>18,285</td>
<td>17,541</td>
<td>19,969</td>
<td>35,859</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>175,494</td>
<td>195,461</td>
<td>210,810</td>
<td>210,373</td>
<td>217,342</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>47,931</td>
<td>57,098</td>
<td>54,894</td>
<td>55,039</td>
<td>50,147</td>
</tr>
<tr>
<td>Less Fund-Raising Expenses Transferred to Non-Operating Income (Expenses)</td>
<td>(43,926)</td>
<td>(44,665)</td>
<td>(47,305)</td>
<td>(52,470)</td>
<td>(59,627)</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>$2,324,545</td>
<td>2,528,467</td>
<td>2,697,371</td>
<td>2,847,103</td>
<td>3,088,799</td>
</tr>
</tbody>
</table>

Income from Operations                         | $89,385      | 211,670      | 91,330       | 178,363      | 214,312      |

### PHILANTHROPY (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philanthropy</td>
<td>$237,666</td>
<td>301,374</td>
<td>231,159</td>
<td>380,500</td>
<td>376,533</td>
</tr>
</tbody>
</table>

### CAPITAL SPENDING (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Spending</td>
<td>$262,371</td>
<td>223,251</td>
<td>258,613</td>
<td>315,282</td>
<td>473,859</td>
</tr>
</tbody>
</table>

### BALANCE SHEET SUMMARY (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets</td>
<td>$6,448,415</td>
<td>6,790,005</td>
<td>7,795,606</td>
<td>8,481,418</td>
<td>8,980,672</td>
</tr>
<tr>
<td>Liabilities</td>
<td>2,550,889</td>
<td>2,848,843</td>
<td>3,562,546</td>
<td>3,337,444</td>
<td>3,614,264</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>$3,897,526</td>
<td>3,941,162</td>
<td>4,233,060</td>
<td>5,143,974</td>
<td>5,366,408</td>
</tr>
</tbody>
</table>
BOARDS OF OVERSEERS AND MANAGERS
as of March 31, 2015

DOUGLAS A. WARNER III
Chair

JAMES D. ROBINSON III
Honorary Chair

MARIE-JOSÉE KRAVIS
Vice Chair of Boards
Chair, Board of Managers,
Sloan Kettering Institute

LOUIS V. GERSTNER, JR.
Honorary Chair of the Board,
Sloan Kettering Institute

SCOTT M. STUART
Vice Chair of Boards
Chair, Board of Managers,
Memorial Hospital

RICHARD I. BEATTIE
Honorary Chair of the Board,
Memorial Hospital

CLIFTON S. ROBBINS
Treasurer

NORMAN C. SELBY
Secretary

CRAIG B. THOMPSON, MD
President and Chief Executive Officer

Frederick R. Adler
Dominic Barton
Richard I. Beattie
Mrs. Edwin M. Burke
Mrs. John J. Byrne
Mrs. Joseph A. Califano, Jr.
Ian M. Cook
Stanley F. Druckenmiller
Anthony B. Evnin, PhD
Roger W. Ferguson, Jr.
Henry A. Fernandez
Steve Forbes
William E. Ford
Richard N. Foster, PhD
Stephen Friedman
Ellen V. Futter
Philip H. Geier, Jr.
Louis V. Gerstner, Jr.
+ Martha V. Glass
Laurie H. Glimcher, MD
Jonathan N. Gray
Bette-Anne Gwathmey
William B. Harrison, Jr.
Benjamin W. Heineman, Jr.
David H. Koch
Marie-Josée Kravis
Paul A. Marks, MD
Donald B. Marron
Kathryn Martin
Jamie C. Nichols
James G. Niven
Hutham S. Olayan
Bruce C. Ratner
Clifton S. Robbins
Alexander T. Robertson
James D. Robinson III
Virginia M. Rometty
David M. Rubenstein
Lewis A. Sanders
Norman C. Selby
Stephen C. Sherrill
Peter J. Solomon
William C. Steere, Jr.
John R. Strangfeld
Scott M. Stuart
Craig B. Thompson, MD
Lucy R. Waletzky, MD
Douglas A. Warner III
Peter Weinberg
Jon Winkelried
Deborah C. Wright
Jeff Zucker
Mortimer B. Zuckerman

+ ex officio

BOARD OF OVERSEERS EMERITI

Mrs. Elmer H. Bobst
Peter O. Crisp
Richard M. Furlaud
James W. Kinnear
Elizabeth J. McCormack, PhD
Benjamin M. Rosen
Jack Rudin
Fayez S. Sarofim

Mrs. Arnold Schwartz
J. McLain Stewart

BOARD OF SCIENTIFIC CONSULTANTS

Frederick R. Applebaum, MD
Richard Axel, MD
Philip A. Cole, MD, PhD
Nancy E. Davidson, MD
Titia de Lange, PhD
James R. Downing, MD
Levi A. Garraway, MD, PhD
Maura L. Gillison, MD, PhD
Joseph L. Goldstein, MD
Gregory Hannon, PhD
James D. Robinson III
Virginia M. Rometty
David M. Rubenstein
Lewis A. Sanders
Norman C. Selby
Stephen C. Sherrill
Peter J. Solomon
William C. Steere, Jr.
John R. Strangfeld
Scott M. Stuart
Craig B. Thompson, MD
Lucy R. Waletzky, MD
Douglas A. Warner III
Peter Weinberg
Jon Winkelried
Deborah C. Wright
Jeff Zucker
Mortimer B. Zuckerman

Caryn Lerman, PhD
Arthur Levinson, PhD
Paul Nurse, PhD
Stanley R. Riddell, MD
James E. Rothman, PhD
Gregory L. Verdine, PhD
Ralph Weissleder, MD, PhD
Irving L. Weissman, MD
| LEADERSHIP |
| MEMORIAL SLOAN KETTERING CANCER CENTER |
| as of March 31, 2015 |

<table>
<thead>
<tr>
<th>NAME</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAIG B. THOMPSON, MD</td>
<td>President and Chief Executive Officer</td>
</tr>
<tr>
<td>KATHRYN MARTIN</td>
<td>Chief Operating Officer</td>
</tr>
<tr>
<td>JOSE B. BASELGA, MD, PhD</td>
<td>Physician-in-Chief and Chief Medical Officer, Memorial Hospital</td>
</tr>
<tr>
<td>JOAN MASSAGUÉ, PhD</td>
<td>Director, Sloan Kettering Institute</td>
</tr>
<tr>
<td>PAUL SABBATINI, MD</td>
<td>Deputy Physician-in-Chief for Clinical Research</td>
</tr>
<tr>
<td>KENT SEPKOWITZ, MD</td>
<td>Deputy Physician-in-Chief for Quality and Safety</td>
</tr>
<tr>
<td>ELIZABETH N. MCCORMICK, MSN, RN, CENP</td>
<td>Senior Vice President and Chief Nursing Officer</td>
</tr>
<tr>
<td>RICHARD R. BARAKAT, MD</td>
<td>Deputy Physician-in-Chief, Regional Care Network and MSK Cancer Alliance</td>
</tr>
<tr>
<td>LARRY NORTON, MD</td>
<td>Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director, Evelyn H. Lauder Breast Center</td>
</tr>
<tr>
<td>MURRAY F. BRENNAN, MD</td>
<td>Vice President, International Programs and Director, International Center</td>
</tr>
<tr>
<td>KERRY BESSEY</td>
<td>Senior Vice President and Chief Human Resources Officer</td>
</tr>
<tr>
<td>CAROLYN B. LEVINE, ESQ.</td>
<td>Deputy General Counsel and Corporate Secretary</td>
</tr>
<tr>
<td>WENDY PERCHICK</td>
<td>Senior Vice President, Strategic Planning and Innovation</td>
</tr>
<tr>
<td>MARGARET M. BURKE</td>
<td>Interim Executive Vice President and Hospital Administrator</td>
</tr>
<tr>
<td>EDWARD J. MAHONEY</td>
<td>Senior Vice President, Facilities Management and Construction</td>
</tr>
<tr>
<td>PATRICIA C. SKARULIS</td>
<td>Senior Vice President and Chief Information Officer</td>
</tr>
<tr>
<td>ERIC COTTINGTON, PhD</td>
<td>Senior Vice President, Research and Technology Management</td>
</tr>
<tr>
<td>CYNTHIA MCCOLLUM</td>
<td>Senior Vice President, Hospital Operations</td>
</tr>
<tr>
<td>CAROL A. SLATTERY</td>
<td>Vice President, Sloan Kettering Institute Administration</td>
</tr>
<tr>
<td>MICHAEL P. GUTNICK</td>
<td>Executive Vice President and Chief Financial Officer</td>
</tr>
<tr>
<td>AMY FRANKEL</td>
<td>Senior Vice President and Chief Communications Officer</td>
</tr>
<tr>
<td>MARK SVENNINGSON</td>
<td>Senior Vice President, Finance and Controller</td>
</tr>
<tr>
<td>JAMES T. HARDEN</td>
<td>Senior Vice President, Strategic Partnerships</td>
</tr>
<tr>
<td>RICHARD K. NAUM</td>
<td>Senior Vice President, Development</td>
</tr>
<tr>
<td>EDWIN TALIAFERO</td>
<td>Vice President, Internal Audit and Compliance and Chief Compliance Officer</td>
</tr>
<tr>
<td>JASON KLEIN</td>
<td>Senior Vice President and Chief Investment Officer</td>
</tr>
<tr>
<td>PAUL NELSON</td>
<td>Senior Vice President, Financial Planning</td>
</tr>
<tr>
<td>RUTH LANDE</td>
<td>Senior Vice President, Patient Revenues</td>
</tr>
<tr>
<td>ROGER N. PARKER, ESQ.</td>
<td>Executive Vice President and General Counsel</td>
</tr>
</tbody>
</table>

For a listing of the members of the professional staff of Memorial Hospital and the Sloan Kettering Institute, please visit www.mskcc.org/annualreport.
### LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES
**MEMORIAL SLOAN KETTERING CANCER CENTER**
as of March 31, 2015

<table>
<thead>
<tr>
<th>LOUIS V. GERSTNER, JR.</th>
<th>CRAIG B. THOMPSON, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman of the Board</td>
<td>President</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>JOAN MASSAGUÉ, PhD</th>
<th>KENNETH J. MARIANS, PhD</th>
<th>LINDA D. BURNLEY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provost</td>
<td>Dean</td>
<td>Associate Dean</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>KATHRYN MARTIN</th>
<th>MICHAEL P. GUTNICK</th>
<th>CAROLYN B. LEVINE, ESQ.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treasurer</td>
<td>Assistant Treasurer</td>
<td>Secretary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TRUSTEES</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard I. Beattie</td>
<td>David H. Koch</td>
<td></td>
</tr>
<tr>
<td>Ellen V. Futter</td>
<td>Marie-Josée Kravis</td>
<td></td>
</tr>
<tr>
<td>Louis V. Gerstner, Jr.</td>
<td>Craig B. Thompson, MD</td>
<td></td>
</tr>
<tr>
<td>Laurie H. Glimcher, MD</td>
<td>Douglas A. Warner III</td>
<td></td>
</tr>
</tbody>
</table>

### SLOAN KETTERING DIVISION
**WEILL CORNELL GRADUATE SCHOOL OF MEDICAL SCIENCES**
as of March 31, 2015

<table>
<thead>
<tr>
<th>JOAN MASSAGUÉ, PhD</th>
<th>KENNETH J. MARIANS, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Director</td>
<td>Director, Graduate Studies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GRADUATE PROGRAM CO-CHAIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIKOLA P. PAVLETICH, PhD</td>
</tr>
<tr>
<td>Biochemistry and Structural Biology Unit</td>
</tr>
<tr>
<td>STEWART SHUMAN, MD, PhD</td>
</tr>
<tr>
<td>Molecular Biology Unit</td>
</tr>
</tbody>
</table>
The Memorial Sloan Kettering Josie Robertson Surgery Center is a first-of-its-kind freestanding outpatient and short-stay cancer surgery facility. It will offer a seamless experience for both patients and their caregivers, providing them with exceptional care using the latest in surgical technology — all in a serene and beautiful environment.

The Josie Robertson Surgery Center (JRSC), made possible by a generous commitment from the Robertson Foundation, will open in 2016. This 16-story, 179,000-square-foot building on York Avenue between East 61st and 62nd Streets will feature 12 operating rooms equipped to provide technologically sophisticated surgical care — including minimally invasive and robot-assisted procedures — on an outpatient basis.

This technology and the expertise of our surgeons and support staff will allow us to perform cancer surgeries that have typically required hospitalization but that now can be performed safely on an outpatient basis, with a single overnight stay. MSK is one of only a handful of cancer hospitals offering this type of leading-edge surgery.

Patient and family engagement is central to the JRSC experience. Education, preoperative preparation, and technological innovation will help patients and families participate in their own care. For example, an online patient portal and mobile device application will help them prepare for the day of surgery, permitting interactions with their team of healthcare professionals as well as giving them the ability to ask questions and monitor their post-surgery progress.

A real-time location system will enable patients and caregivers to move freely around the JRSC rather than remain tethered to waiting rooms. Twenty-eight private postoperative recovery rooms with private bathrooms will offer sleeper sofas and recliners for caregivers.

The facility is designed to encourage patients to get out of their rooms and walk as well as to engage them and their families in actively participating in their care, both in the facility and at home after discharge.
THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Memorial Sloan Kettering benefited enormously from the generosity of thousands of donors who made contributions large and small to the Campaign.

Fueled by over a million gifts received from supporters around the world, the Campaign for Memorial Sloan Kettering maintained its strong forward progress in 2014. As of December 31, the Campaign had recorded $3.53 billion in gifts and pledges, with two years still remaining in the historic fundraising effort.

From its outset, the Campaign has benefited from the leadership of co-chairs Douglas A. Warner III and Louis V. Gerstner, Jr., who work closely with President Craig B. Thompson and their colleagues on the MSK Board to generate philanthropic support for MSK’s most pressing needs.

The Campaign achieved impressive results at every gift level during the year, which ended on a high note: A total of $83.4 million in gifts and pledges were recorded in December. Under the direction of Anne M. McSweeney and Richard K. Naum, the MSK Development Office has built a solid foundation for ongoing achievement that will be crucial in the years ahead.

It was another standout year for MSK’s athletic fundraising initiatives, including Cycle for Survival and Fred’s Team, which help spread the word about the important work being done at MSK while engaging thousands of supporters in the fight against cancer. Together with Equinox, the event’s founding partner, Cycle for Survival has become the fastest-growing such event in the country, attracting 85,000 new donors in 2014 — an increase of 22 percent over the previous year. Since its founding in 2007, Cycle for Survival has raised more than $76.4 million for research into rare cancers.

The Campaign’s strong continued achievement is inspired by the extraordinary accomplishments of MSK’s talented physicians and scientists, and the generous support that benefactors provide is helping to drive further progress, now and in the years to come.
<table>
<thead>
<tr>
<th>$100,000,000 OR MORE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Estate of Geoffrey Beene</td>
</tr>
<tr>
<td>Henry and Marie-Josée Kravis</td>
</tr>
<tr>
<td>The Starr Foundation</td>
</tr>
<tr>
<td>Mortimer B. Zuckerman</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$50,000,000—$99,999,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley F. and Fiona Druckenmiller</td>
</tr>
<tr>
<td>Mr. and Mrs. William H. Goodwin, Jr., and the Commonwealth Foundation for Cancer Research</td>
</tr>
<tr>
<td>David H. Koch</td>
</tr>
<tr>
<td>The Leonard and Evelyn Lauder Foundation</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$25,000,000—$49,999,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Atlantic Philanthropies</td>
</tr>
<tr>
<td>Jack and Dorothy Byrne Foundation</td>
</tr>
<tr>
<td>The Louis V. Gerstner, Jr. Foundation, Inc.</td>
</tr>
<tr>
<td>The Sidney Kimmel Foundation</td>
</tr>
<tr>
<td>Prostate Cancer Foundation</td>
</tr>
<tr>
<td>The Tow Foundation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$20,000,000—$24,999,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anonymous</td>
</tr>
<tr>
<td>The Breast Cancer Research Foundation</td>
</tr>
<tr>
<td>The Society of MSK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$10,000,000—$19,999,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anonymous</td>
</tr>
<tr>
<td>Trust of Burton Abrams</td>
</tr>
<tr>
<td>The Elmer and Mamdouha Bobst Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Raymond T. Dalio</td>
</tr>
<tr>
<td>The Stephen and Barbara Friedman Foundation</td>
</tr>
<tr>
<td>Alan and Sandra Gerry</td>
</tr>
<tr>
<td>The Arnold and Arlene Goldstein Family Foundation</td>
</tr>
<tr>
<td>Trust of Steven A. Greenberg</td>
</tr>
<tr>
<td>The Donald B. and Catherine C. Marron Foundation</td>
</tr>
<tr>
<td>Mr. and Mrs. Milton Petrie</td>
</tr>
<tr>
<td>Laurance S. Rockefeller</td>
</tr>
<tr>
<td>The Louis V. Gerstner, Jr. Foundation, Inc.</td>
</tr>
<tr>
<td>Prostate Cancer Foundation</td>
</tr>
<tr>
<td>The Tow Foundation</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Gloria Miner
The Nadassy Foundation
The New York Community Trust
The Samuel I. Newhouse Foundation
Stavros S. Niarchos Foundation
Nonna’s Garden Foundation
Ronald O. Perelman
Estate of Catherine R. Price
RBC Decathlon
The Jim and Linda Robinson Foundation
Jack Rudin
The Louis & Rachel Rudin Foundation
The May & Samuel Rudin Family Foundation
Damon Runyon Cancer Research Foundation
Estate of Marilyn L. Schaef er
Estate of Grace A. Shapiro
Mr. and Mrs. H. Virgil Sherrill
The Joachim Silberman Family
Paul E. Singer
Joan and Joel Smilow
The Sontag Foundation
Sportsmen for Charity
George Strawbridge, Jr.
Mr. and Mrs. Scott Stuart
The Joseph and Arlene Taub Foundation
Margarett a J. Taylor
Estate of Richmond E. Thompson
Trust of Jane Toplitt
TOSA Foundation
Trust of Bessie Weintraub

Cancer Research Institute
Robert B. Catell
John and Michael Chandris
The Laura Chang and Arnold Chavkin Charitable Fund
Trust of Charles P. Ciaffone
Trust of George Clegg
Simon & Eve Colin Foundation, Inc.
The Comer Science and Education Foundation
The Connecticut Sports Foundation
Trust of James J. Corbalis, Jr.
Sharon Levine Corzine
Trust of Caroline S. Coulton
The Countess Moira Foundation
Mr. and Mrs. Peter O. Crisp
Cure Breast Cancer Foundation, Inc.
Estate of Helen M. Curry
Trust of Margaret E. D ahm
Dennis D. Dammerman
The Dana Foundation
Mr. and Mrs. Marvin H. Davidson
Trust of Myra Davis
Estate of Charles E. Dillman
Gloria DiPietro-Cooper
Michael Douglas and Catherine Zeta-Jones
Trust of Nancy K. Dunn
The Ellison Medical Foundation
Entertainment Industry Foundation
Estate of Selma Ettenberg
The Eunice Foundation
Estate of Harry Fagen
Farmer Family Foundation
Trust of Harold Farrington
The John K. Figge Family
Estate of Barbara D. Finberg
The Jerome and Anne C. Fisher Charitable Foundation
Flight Attendant Medical Research Institute
The Stephanie and Lawrence Flinn, Jr. Charitable Trust
Estate of Harry N. Forman
Lorraine Friedman
Trust of Oscar H. Friedman
Friezo Family Foundation
Fund for Ophthalmic Knowledge
Estate of Frank H. Gabriel
Gabrielle’s Angel Foundation
Sara Gadd
Estate of Thomas Gardiner
Trust of Virginia L. Garrison
Trust of Florence K. Geffen
The Lawrence M. Gelb Foundation, Inc.
Richard L. Gelb
Genentech
General Electric Company
Eileen Genet Fund for Ovarian Cancer Research and Prevention
Trust of Josephine A. Gilmore
Estate of Thelma Gish
GIST Cancer Awareness Foundation
GIST Cancer Research Fund
Estate of Anna H. Gleason

Miriam and Alan Goldberg
The Joyce & Irving Goldman Family Foundation
Golfers Against Cancer Foundation
The Gordon Fund
Trust of Jane H. Gordon
Grass Family Foundation
Mind y and Jon Gray
The Marion and Louis Grossman Foundation
Mr. and Mrs. Robert Grossman
Trust of Helen Guerin
Kate Medina Guthart and Leo A. Guthart
Hackers for Hope
Mr. and Mrs. James J. Hagan
Estate of Joseph M. Hand
Mr. and Mrs. John J. Hannan
Estate of Margaret H. Hanson
Stephen P. Hanson
Jamie and Jeffrey Harris
Gladys and Roland Harriman Foundation
The Heckscher Foundation for Children
Marie B. Hilliard
The Charles and Marjorie Holloway Foundation, Inc.
Estate of Brian W. Holman
Estate of Harriet Huber
William Lawrence & Blanche Hughes Foundation
Estate of Dorris J. Hutchison
Leslie Hutchison and Virginia Shaw
IBM Corporation
Inspire 2 Live Foundation
Barbara and Tom Israel
The JPB Foundation
Trust of Harry C. Jaecher, Jr.
Estate of Clarence W. Johnson
Estate of Wilda Johnson
Trust of Marion Kahn
Katzman Family Foundation
Estate of Mary B. Ketcham
Estate of John W. Knox
Mr. and Mrs. Matania Kochavi
Estate of Rosemarie Kruilsh
The Thomas G. Labrecque Foundation
Trust of Grace Fay Lamb
Philippe Laub
Estate of Wilhelmina LeJeune
Estate of Ada Leventhal
Estate of Harold F. Levinson
Leon Levy Foundation
The LisaBeth Foundation
The Litwin Foundation
Robert S. Ludwig and Gwenth y E. Rankin
Lymphoma Research Foundation
Mr. and Mrs. J. Randall MacDonald
Mr. and Mrs. Joel Mallah
The Lois H. Mann Charitable Foundation
Margaux’s Miracle Foundation
Mrs. Joseph L. Martino
Mrs. William L. Matheson
Merrill Lynch & Co. Foundation, Inc.
Fred and Marie-Noelle Meyer
Estate of Wilma S. Mills

$1,000,000—$2,499,999

Allen & Company, Inc.
Mr. and Mrs. Andrew B. Abramson
Mr. and Mrs. Frederick R. Adler
Alex’s Lemonade Stand
Mr. and Mrs. Fred M. Alger III
Estate of Billie H. Allen
Alliance for Cancer Gene Therapy
Stephen and Madeline Ambinder
John M. Angelo and Judy Hart Angelo
Anonymous
Estate of Roone P. Arledge
The Award of Courage Corporation
Roger and Lori Bahnik
The Batishwa Fellowship
Trust of Edgar D. Baumgartner
Mr. and Mrs. Daniel C. Benton
Estate of Irma Berg
Allen and Joan Bildner
The Anita and Leonard Boxer Family Foundation
Breast Cancer Alliance, Inc.
Mr. and Mrs. Viatcheslav I. Brecht
Peter and Linda Bren
The Andrea and Charles Bronfman Philanthropies, Inc.
Estate of Helen Brown
Trust of Emil A. Buelens
Estate of Diane B. Burkhart
The Burnett Foundation
Burroughs Wellcome Fund

Donors to the Campaign for Memorial Sloan Kettering
Jim and Mary Jane Milton
Estate of Robert C. Mitchell
Trust of Douglas C. Mohl
The Ambrose Monell Foundation
Estate of Warren A. Montel
Morgan Stanley
The William T. Morris Foundation
Trust of Anna V. Muller
Estate of Elaine Muller
Mushett Family Foundation, Inc.
Trust of Saul Nathanson
Dr. Burton and Ellen Needles
The New York Yankees Foundation
The Olayan Group
Francine Farnes
Pediatric Cancer Foundation
Estate of Frederick Pelda
John and Francie Pepper
Trust of Elizabeth L. Perkins
Perry Capital LLC
Estate of Jeannine Poli
Laura and Christopher A. Pucillo
Sara and Iser Rabinovitz
Mrs. Katharine J. Rayner
Charles H. Revson Foundation
RJR Oncodermatology Fund
Estate of Edith Roberts
Estate of Josephine T. Robertson
Estate of Anne Morales Rodgers
Mary Jo and Brian Rogers
The Felix and Elizabeth Rohatyn Foundation
The Laura Rosenberg Foundation, Inc.
Estate of Lillian E. Rosenmerkel
M. Steven and S. David Silbermann
Mr. and Mrs. Herbert J. Siegel
Alfred J. and Stephanie Shuman through
Mr. and Mrs. David K. Storrs
The Margaret Dorrance Strawbridge Foundation
of PA
The Sussman Family Fund
Trust of M. Allen Swift
Tang Family Foundation
Tarnopol Family Foundation
Terry Fox Run for Cancer Research (NYC)
Trust of Irving Tirkfield
Estate of Lillian Tomek
The Beth C. Tortolani Foundation
Anthony and Carole Trapani
The Trump Group
Tudor Investment Corporation
Mr. and Mrs. Thomas Tuttle
Universal Network Television
The V Foundation for Cancer Research
Trust of Virginia and Edward Van Dalson
Vanguard Charitable Endowment Fund
Estate of William N. Vaughan
Trust of Edward W. Vollintine
Lucy B. Waletzky, MD
Joan and Sanford I. Weill
Louis and Jane Weinstock
The Lillian S. Wells Foundation, Inc.
Mr. and Mrs. Clay T. Whitehead
Estate of Carolyn H. Wilson
Winterburn Foundation
Diana S. Wister
The Meryl and Charles Witmer Charitable Foundation
The Wolfensohn Family Foundation
Mr. and Mrs. Robert Wright
Zev’s Fund Inc.
Ziff Brothers Investment, LLC

$500,000—$999,999
Estate of Margaret W. Schafer
Estate of Catherine M. Schooley
The Beatrice & Samuel A. Seaver Foundation
Mr. and Mrs. Norman C. Selby
Richard and Clara Serra
Dr. David E. and Beth Kobliner Shaw
The Peter M. Sacerdote Foundation
Lewis A. Sanders
Faye Sarofim & Co.

Betty, James, and Thomas Blake
(The Thomas Blake, Sr. Memorial Fund)
The Blue Dot Foundation
Trust of Ethelvida Boehme
Estate of William Boehme
Mr. and Mrs. David Boies
Estate of Marcel S. Bollag
Trust of Frederick W. Bonacker, Jr.
The Bondi Foundation
Estate of Adele Bozio
Trust of Nancy J. Bradford
Terri Brodeur Breast Cancer Foundation
Trust of Dorothy Fielder Brown
Mrs. Edwin M. Burke
Hilary and Joseph A. Califano, Jr.
The Cancer Research Foundation of America
The Richard E. Capri Foundation on behalf of the
Wolf Family
Estate of Richard B. Carman
Mr. and Mrs. Kenneth Carmel
The Tina and Richard V. Carolan Foundation
James & Patricia Cayne Charitable Trust
The Y. C. Ho/Helen and Michael Chiang Foundation
Trust of Betty R. CIAfone
Citigroup
Estate of Harry J. Colish
The Julien Collot Foundation, Inc.
Constant Convocation Center
Cookies for Kids’ Cancer
The Elaine Terner Cooper Foundation
Trust of Faye Copeland
Estate of Howard Corlies
Estate of Leonard Corso
Chandler Cox Foundation
Estate of Helen M. Cramer
CureSearch for Children’s Cancer
Mr. and Mrs. Rafic Dahan
John and Georgia DallePezze
Davis Charitable Foundation
Estate of Sandra Newman Dawson
The Thompson Dean Family Foundation
Estate of Carol T. Decker
The DeGroot Family Foundation
Annette and Oscar de la Renta
Dempster Charitable Trust
Deutsche Bank Securities Inc.
Trust of James Douglas
The Walter S. and Lucienne B. Driskill Foundation
Estate of Louis Duenweg
Trust of Phyllis K. Dunn
The Emerald Foundation
Mr. and Mrs. David Epstein
Trust of Virginia J. Faber
Arthur Falcone
Estate of Katie Fasal
Estate of Beatrice Feinstein
Paul Felzen
The Fibrolamellar Cancer Foundation
Estate of Alice H. Ficht
Trust of Alice D. Fiedler
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Marie Finch
Estate of Susan L. Fischer
The Michael J. Fox Foundation
Trust of Ira S. French
Trust of Dr. Benjamin T. Friedman
Trust of Edith West Friedman
Estate of Maud Gallagher
The Gateway for Cancer Research
Estate of Joseph G. Gaumont
Estate of Selma Geller
Joe Gellert
Estate of Lillian B. George
The Gerber Foundation
The Aaron and Betty Gilman Family Foundation
Estate of William J. Glassgow
Estate of Robert E. Gleason
Mr. and Mrs. Robert S. Goldberg
The Horace W. Goldsmith Foundation
Alfred G. & Hope F. Goldstein Fund
Estate of Helen M. Golen
Mr. and Mrs. Alan J. Greene
Trust of Phyllis A. Greene
Trust of Richard M. Greifer
Estate of Edythe Griffinger
Peter M. Gugenheimer
The Marc Haas Foundation
Mr. and Mrs. William W. Haerther, Jr.
Estate of Ethel V. Haldeman
Evelyn A. J. Hall Charitable Trust
Mr. and Mrs. Stephen L. Hammerman
Estate of Olga V. Hargis
Mr. and Mrs. William B. Harrison, Jr.
Estate of Judith B. Helfant
Trust of Richard V. Henry, Jr.
Estate of Ruth H. Hewlett
Marie B. Hilliard
Trust of Milan M. Holdorf
Trust of Benjamin Holmes
Trust of Karla Homburger
Hope Funds for Cancer Research
Estate of Claire Hughes-Glassow
The Patricia M. Hynes and Roy L. Reardon Foundation
Deanne and Arthur Indursky
Invest for Children, a Foundation of Investindustrial
Mrs. H. Anthony Ittelson
The Rona Jaffe Foundation
Johnson & Johnson
Estate of Horace A. Jones
Fritz and Adelaide Kauffmann Foundation
Mr. and Mrs. Robert B. Kay
Kinetics Foundation
Estate of Joan E. Kinley
Estate of Hazel V. Knapp
Estate of Ruth Koch
The Koodish Family Charitable Trust
The Kronthal Family
The Jacob & Valeria Langeloth Foundation
Trust of Charles T. Larus
Lazard Capital Markets
The Lerner Foundation

Estate of Anne Leventon
Dr. Nancy Alpern Levin
Life Raft Group
Estate of Lillian Light
Trust of Catherine M. Lincoln
Harry J. Lloyd Charitable Trust
Trust of Martin C. and Margaret V. Lohsen
Trust of Louis J. Lombardi
Mr. and Mrs. Edward Lundy
Estate of Evelyn P. Lyon
Earle I. Mack Foundation
Estate of Lucille Knowles Friedman Mann
March of Dimes Foundation
Estate of Anne Markowitz
Trust of Anthony J. Masard
Max Cure Foundation
Mr. and Mrs. Louis V. Mazzella
Nancy and Paul McCartney
Trust of John C. McCormick
Mr. and Mrs. Thomas H. McCullough
The James S. McDonnell Foundation
Estate of Donald G. McKeon
MeadWestvaco Corporation
Estate of Ralph Nelson
Estate of Ruth Vitow Messias
Trust of Russell A. Meyer
The Milbank Foundation for Rehabilitation
J. P. Morgan Chase
The Norman M. Morris Foundation
Trust of Paula Moss
Mr. and Mrs. Charles H. Mott
Movember
Muscular Dystrophy Association
The National Brain Tumor Society
National Childhood Cancer Foundation
Carole and Raymond Neag
News Corporation
Occidental Petroleum Corporation
Trust of Melba M. O'Connell
The Sylvan and Ann Oestreicher Foundation
Trust of Melba M. O'Connell
The National Multiple Sclerosis Society

deine and Arthur Indursky
Invest for Children, a Foundation of Investindustrial
Mrs. H. Anthony Ittelson
The Rona Jaffe Foundation
Johnson & Johnson
Estate of Horace A. Jones
Fritz and Adelaide Kauffmann Foundation
Mr. and Mrs. Robert B. Kay
Kinetics Foundation
Estate of Joan E. Kinley
Estate of Hazel V. Knapp
Estate of Ruth Koch
The Koodish Family Charitable Trust
The Kronthal Family
The Jacob & Valeria Langeloth Foundation
Trust of Charles T. Larus
Lazard Capital Markets
The Lerner Foundation

Estate of Anne Leventon
Dr. Nancy Alpern Levin
Life Raft Group
Estate of Lillian Light
Trust of Catherine M. Lincoln
Harry J. Lloyd Charitable Trust
Trust of Martin C. and Margaret V. Lohsen
Trust of Louis J. Lombardi
Mr. and Mrs. Edward Lundy
Estate of Evelyn P. Lyon
Earle I. Mack Foundation
Estate of Lucille Knowles Friedman Mann
March of Dimes Foundation
Estate of Anne Markowitz
Trust of Anthony J. Masard
Max Cure Foundation
Mr. and Mrs. Louis V. Mazzella
Nancy and Paul McCartney
Trust of John C. McCormick
Mr. and Mrs. Thomas H. McCullough
The James S. McDonnell Foundation
Estate of Donald G. McKeon
MeadWestvaco Corporation
Estate of Ralph Nelson
Estate of Ruth Vitow Messias
Trust of Russell A. Meyer
The Milbank Foundation for Rehabilitation
J. P. Morgan Chase
The Norman M. Morris Foundation
Trust of Paula Moss
Mr. and Mrs. Charles H. Mott
Movember
Muscular Dystrophy Association
The National Brain Tumor Society
National Childhood Cancer Foundation
Carole and Raymond Neag
News Corporation
Occidental Petroleum Corporation
Trust of Melba M. O'Connell
The Sylvan and Ann Oestreicher Foundation
Trust of Melba M. O'Connell
The National Multiple Sclerosis Society

Recanati Foundation
John Bradbury Reed
Trust of Irene Dorothy Reel
Estate of Muriel G. Reich
Estate of Agnes Rezler
Estate of Richard A. Riecker
Drs. Helena and David Rodbard
Alexander J. Roepers
Shafi Roepers
Trust of William C. Rogers
Mr. and Mrs. Stephen J. Rosenthal
The Arthur Ross Foundation, Inc.
Trust of Edward G. Ryder
The Raymond & Beverly Sackler Fund for the Arts and Sciences
Dr. Nathan E. Saint-Amant
Sarcoma Foundation of America
Estate of George W. Schneider III
Estate of Alana M. Schuster
The Seraph Foundation
Trust of William and Isabelle Sherlock
Evelyn B. Simmons Charitable Trust
Suzanne Cohn Simon
Estate of Ann Smith
Trust of Barbara K. Snader
Estate of William E. Snee
The Society of MSK Associates Committee
Estate of Katherine R. Sonneman
Spin4Survival
Trust of Barbara A. Stapleton
Estate of Helen E. Steadman
Bonnie and Steven E. Stern
Trust of Charles M. Stevenson
The Mel Stottlemeyer Myeloma Foundation
Mr. and Mrs. Paul A. Street
Trust of James Strobridge
Mrs. Laure Sudreau-Ripple
The Michael Swig Foundation
Ping Y. Tai Foundation
J. T. Tai & Co. Foundation
The Craig D. Tiftord Foundation, Inc.
Barbara Davies Troisi Foundation
Thomas N. Tryforos
Estate of Stanley F. Tucker
Daniel P. and Grace I. Tully Foundation
Turner Construction Company
Twenty-First Century Fox, Inc.
The Tyler Foundation
United Way of Tri-State
Uniting Against Lung Cancer
Trust of Ward M. Vanderpool
Variety – The Children's Charity
Richard C. Vergobbi
Estate of Christine Villano
The Warner Foundation, Inc.
The Wasley Family Foundation
Estate of Ingeborg K. Watson
Trust of Thomas J. Watson, Jr.
Estate of Ruth C. Weissmann
Mr. and Mrs. Harold S. Wertheimer
Trust of Reamer W. Wigle
Trust of Richard A. Yudkin
The Brightwater Fund, Gloria Jarecki

$250,000—$499,999

Trust of George Aaron
Accelerate Brain Cancer Cure (ABC2) Foundation
Estate of John D. Adams, Jr.
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Adenoid Cystic Carcinoma Research Foundation
The Louis & Bessie Adler Foundation
The Alliance Against ASPS Foundation
Trust of Eileen Alpert
Alzheimer’s Association
American Asthma Foundation
American Health Assistance Foundation
The American Ireland Fund
The Ametek Foundation, Inc.
Dorothy A. Anderson
Anonymous
Estate of Mark J. Anton
Estate of Anita S. Appel
Mr. and Mrs. Frank W. Appleton, Jr.
Arms Wide Open Childhood Cancer Foundation
Joyce Ashley
Estate of Rose Ashton-Irvine
Avon Foundation
Estate of William C. Bahn, Jr.
The Banbury Fund
Estate of Iris Baranof
Trust of Margaret D. Barber
Estate of Florence Barrack
Estate of Marcia Batten
Betsy L. Battle
Trust of Gertrude E. Beck
Estate of Grace Becker
Cheryl K. Beebe and James A. Grimm
Estate of Ethel A. Bell
Trust of Virginia Poole Benjamin
Corinne Berezuk and Michael Stieber
Bergstein Family Foundation
Estate of Gertrude G. Bernstein
The Lisa E. Bilotti Foundation
The Nancy and Robert S. Blank Foundation
Trust of Ronald M. Blau
Estate of Ida Bloom
Albert and Betty Bodian
Antoinette E. & Herman Boehm Foundation
Estate of Marthe Bonneau
Trust of Lillian Borchardt
The Louis L. Borick Foundation
The Albert C. Bostwick Foundation
Mr. and Mrs. Kevin A. Bousquette
Trust of Alice M. Branch
The Braver Foundation
Bridgemill Foundation
Estate of Paul P. Brielloff
Bright Focus
The Brightwater Fund, Gloria Jarecki
The Honorable Tina Brozman Foundation
Estate of Madalyn B. Bryant
The Bugs Fund
Tory Burch
Estate of Marian Butler
Cancer Support Services, Inc.
The Paul Robert Carey Foundation
Caring for Carcinoid Foundation
Mr. and Mrs. Michael Carr
Estate of Georgia M. Catrini
Trust of Ruth C. Celarek
Estate of Burdette G. Chamberlin
Trust of Cicely J. Chandler
Joan Chorney
Chris4Life Colon Cancer Foundation
Florence Chu, MD
CIBC World Markets Corporation
The Clark Foundation
Estate of Gerald Clements
Estate of Dorothy L. Cobb
Trust of Joan F. Cobb
Frances B. Cohen
Mr. and Mrs. John K. Colgate, Jr.
Terry Collins
The Community Foundation for Northern Virginia – Hanlon Family Fund
Estate of Robert L. Conley
Estate of Lillian Copperman
Carlos A. Cordeiro Foundation
Estate of Leonard Cossack
Frederic R. Coudert Foundation
The Cowles Charitable Trust
Estate of Mary O. Craft
Cure Childhood Cancer
Estate of Edna W. Curl
Filomen M. D’Agostino Foundation Corp.
Estate of Thomas R. Daly
Estate of Rosetta Damilano
Trust of DeWitt S. Davidson
Trust of Richard L. Davies
The Arthur Vining Davis Foundations
Estate of Frederick W. Davis
Estate of Leonard Davis
Trust of Marion E. Dean
Deborah A. DeCotis
Estate of Lorraine J. Dehoog
Trust of Carolyn B. Denney
The De Rosa Foundation for Colon Cancer Research and Prevention
Hester Diamond Foundation
The Dickson Foundation
Estate of Evelyn Z. Diehl
The DiMenna Foundation, Inc.
Elizabeth R. Miller and James G. Dinan and The Dinan Family Foundation
Elizabeth K. Dollard Charitable Trust
William C. Dowling, Jr. Foundation
Estate of Laura D. Eastman
The Eberstadt-Kuffner Fund Inc.
Mr. and Mrs. Thomas J. Edelman
Mr. and Mrs. Barclay Ehrler
Eli Lilly & Co.
Estate of Rita H. Schaefer Elliott
Empire Blue Cross & Blue Shield
The Charles Engelhard Foundation
Mr. and Mrs. Israel Englander
Esophageal Cancer Education Foundation
Trust of June K. Evans
Trust of Lillian Evans
Lord Evans of Watford
Trust of Sarah W. Ewing
Mr. and Mrs. Barton Faber
Estate of Giuliana Fantini
Trust of Mary E. Farrell
Estate of Ralph R. Feigelson
The Feinstein Family Foundation
The Isabel, Harold, and Gerry Feld Fund for Bereavement
Hilary Carla Feshbach
Mrs. Frederick Fialkow
Estate of Selma Fine
The Grace J. Fippinger Foundation, Inc.
First Quality Enterprises, Inc.
Jeanne Donovan Fisher
The Jodi Spiegel Fisher Cancer Foundation
Aaron Fleischman and Lin Lougheed Foundation
The Floren Family Foundation
Fondazione Italiana
For the Love of Life
Trust of William Forbes
Foundation 14
The Evan Frankel Foundation
Mr. and Mrs. Lewis Frankfort
Trust of Jill and Jayne Franklin
Frazier Foundation
The Edna R. Fredel Charitable Lead Annuity Trust
Estate of Frank O. Fredericks
Free to Breathe
The Fribourg Foundation
Estate of Gerard M. Friedman
The Anna Fuller Fund
Richard M. Furlaud
Estate of Leonard Galasso
Estate of Regina M. Gallichio
Estate of Norman D. Galloway
Mr. and Mrs. Robert M. Gardiner
Trust of Esther B. Garnet
Trust of Frances L. Gatterdam
Estate of Mildred B. Gehre
Leonardo Giambrone
The Albert and Pearl Ginsberg Foundation
Liane Ginsberg
The Glades Foundation
Mr. and Mrs. Eugene J. Glaser
Trust of Marc S. Goldberg
Corinne and Daniel Goldman
Susan Wallack Goldstein
Arthur A. Gosnell
Estate of Barbara Grace
Graf Diamonds
Granary Associates
The Grateful Foundation, Inc.
Estate of Eldridge A. Greenlee
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Grinberg Family Foundation
Virginia and Howard Groombridge
Mr. and Mrs. Martin D. Gross
Trust of William Gross
Shoshanna and Josh Gruss
Gurwitch Products
Robert C. Halboth
Mrs. Melville W. Hall
Trust of Florence M. Hammer
Mr. and Mrs. Jose Kuri Harfush
Susanne and Shelley Harrison
Mr. and Mrs. Robert L. Harteveldt
Trust of Abraham Hases
Estate of Katherine Hawrylow
Estate of Irma Hayes
Hecht & Company Philanthropic Foundation
Mr. and Mrs. Charles Heimbold, Jr.
Cherie Henderson and David Poppe
Heyman-Merrin Family Foundation
Brian J. Higgins
The Hillcrest Foundation
James and Angela Ho
The Catie Hoch Foundation
Estate of Laverne Hodges
Estate of Martha Holloway
Mr. and Mrs. D. Gregory Horrigan
Estate of Chester S. Howard
Estate of Karen L. Hudson
The Howard Hughes Medical Institute
Syde Hurdus Foundation, Inc.
IBM International Foundation
Bruce H. Jacobs
Trust of Clyde H. Jacobs
Harry A. Jacobs, Jr.
Janssen Pharmaceutical Products LP
Estate of Mira Jelin
The JMB Hope Foundation
The Robert Wood Johnson Foundation
Estate of Al Jolson
Estate of Robert L. Jones
Max Kade Foundation, Inc.
Estate of William Kantor
Estate of Helen Keena
Trust of Fenton O. Keister
Robert J. Keller
The John R. Kennedy Foundation
Estate of Patricia A. Kerrigan
Estate of Ursula A. Kildea
Pamela and Dwaine Kimm
Trust of Estelle Knapp
Trust of Paul and Fran Knight
The Kors Le Pere Foundation
Joel Koschitzky
The Gwen L. Kosinski Foundation
Mr. and Mrs. Marvin H. Koslow
The Fred W. Kramer Charitable Trust
Mr. and Mrs. Robert A. Kramer
Cheryl Gordon Krongard
Trust of Walter C. Kronke
Estate of Harriette H. Kussin
Estate of Sidney Lacher
Lake Road Foundation
The Lakeside Foundation
Mr. and Mrs. Joseph M. La Motta
Estate of Harriet L. Lampert
Vivian F. Laube
Lavelle Fund for the Blind, Inc.
Betty Reid Lawson
The Iris and Junming Le Foundation
Lead Annuity Trust
Trust of Joseph Lebednik
The Richard S. and Karen LeFrak Charitable Foundation
In memory of Stacey Leonidis
Estate of Donald LeRoy
Leukemia Research Foundation
Mr. and Mrs. Allan L. Levey
Fran and Ralph Levine
Trust of Leena Levy
The Anne Boyd Lichtenstein Foundation
Estate of Helen Lieber
The Bertha and Isaac Liberman Foundation, Inc.
Estate of John E. Liebmann
Pauline H. Lin
Estate of Leah W. Linn
Live4Life Foundation
Estate of Marian J. Looser
Lung Cancer Research Foundation
LUNGevity Foundation
MacDonald-Peterson Foundation
MacMillan Family Foundation
Estate of Julian Malkiel
Manhasset Women's Coalition Against Breast Cancer
Estate of Albert Manning
Estate of Marvin Margolies
Mrs. John L. Marion
Susan and Morris Mark
Trust of Sarah H. Marks
The Marmot Foundation
Estate of Edith Lipphardt Martens
Estate of Elizabeth Martin
Trust of Richard and Betty Martin
Estate of Ann L. Martinez
The Lucille and Paul Maslin Foundation
Trust of Cecelia Matarazzo
Estate of Michael Matchen
Estate of Harry H. Maus
Paul S. May
The Mayday Fund
The Helen & William Mazer Foundation
MBNA America Bank
The MBNA Education Foundation
Mary Jane McCarthy
The Michael W. McCarthy Foundation
Mr. and Mrs. Thomas R. McCullough
Mr. and Mrs. Jay H. McDowell
Estate of Charles McGreavy
Mr. and Mrs. Thomas E. Mcinerney
Estate of Mary T. McKibbin
Estate of Ann L. Martinez
The New York City Comptroller's Charitable Foundation
The New York Company for Human Needs
The Newport Foundation
Estate of Robert K. and Joan M. Newell
Estate of Florence S. Nilsson
James G. Niven
The Lyla Nsouli Foundation for Children's Brain Cancer Research
Trust of Robert M. Ochs
The Okonite Company
Grace Oughton Cancer Foundation
The Ovarian Cancer Research Fund
The William & Jane Overman Foundation
Eileen and James A. Paduano
Parfums de Coeur Ltd.
Rosalind and Kenneth Pearlman
PepsiCo Foundation, Inc.
Calvin Klein Women’s Foundation
Estate of Ann Perkins
Estate of Claude E. Petruzzelli
Pin Down Bladder Cancer
Mr. and Mrs. Jeroen Henk L. Pit
Jean D. Pitcher
Jerry W. Pittman
Plastic Surgery Foundation
Polo Ralph Lauren Corporation
Estate of Elizabeth Polotaye
Trust of Helen M. Price
Estate of Seymour Price
Prudential Financial, Inc.
Robert Pufahl
Purdue Pharma LP
Patricia A. Quick Charitable Trust
Trust of Harriet C. Rath
James N. Rentas 5K Run/Walk
Trust of Anne Ressner
Estate of Walter E. Rex III
The Rice Family Foundation
Louise & Frank Ring
The Ritter Family Foundation
Irene Ritter Foundation
The Andréa Rizzo Dance Therapy Fund
Trust of Lillian Robbins
Mr. and Mrs. Stephen Robert
Robin Hood Foundation
The Reuven Merker Charitable Foundation, Inc.
Mesothelioma Applied Research Fund
Estate of Despina Messinesi
Mr. Robert A. Metzler
Peter Michael Foundation
Trust of Russell H. Michel
Mrs. Minot K. Miliken
Estate of Dorothea K. Money
Young Ae Lim and Joonsik Moon
Trust of Anny S. Moore
Diana M. Moore
Yvonne & Arthur Moretti
Ronald and Brenda Morey
Trust of Edmund L. Murray
Mustaches For Kids
Trust of Louise F. Neely
Craig H. Neilsen Foundation
Estate of Ann M. Nelson
Muriel Neumann
The Newport Foundation
Estate of Jane M. Nicholson
Trust of Florence S. Nilsson
James G. Niven
The Lyla Nsouli Foundation for Children's Brain Cancer Research
Trust of Robert M. Ochs
The Okonite Company
Grace Oughton Cancer Foundation
The Ovarian Cancer Research Fund
The William & Jane Overman Foundation
Eileen and James A. Paduano
Parfums de Coeur Ltd.
Rosalind and Kenneth Pearlman
PepsiCo Foundation, Inc.
Estate of Ann Perkins
Estate of Claude E. Petruzzelli
Pin Down Bladder Cancer
Mr. and Mrs. Jeroen Henk L. Pit
Jean D. Pitcher
Jerry W. Pittman
Plastic Surgery Foundation
Polo Ralph Lauren Corporation
Estate of Elizabeth Polotaye
Trust of Helen M. Price
Estate of Seymour Price
Prudential Financial, Inc.
Robert Pufahl
Purdue Pharma LP
Patricia A. Quick Charitable Trust
Trust of Harriet C. Rath
James N. Rentas 5K Run/Walk
Trust of Anne Ressner
Estate of Walter E. Rex III
The Rice Family Foundation
Louise & Frank Ring
The Ritter Family Foundation
Irene Ritter Foundation
The Andréa Rizzo Dance Therapy Fund
Trust of Lillian Robbins
Mr. and Mrs. Stephen Robert
Robin Hood Foundation
The Reuven Merker Charitable Foundation, Inc.
Mesothelioma Applied Research Fund
Estate of Despina Messinesi
Mr. Robert A. Metzler
Peter Michael Foundation
Trust of Russell H. Michel
Mrs. Minot K. Miliken
Estate of Dorothea K. Money
Young Ae Lim and Joonsik Moon
Trust of Anny S. Moore
Diana M. Moore
Yvonne & Arthur Moretti
Ronald and Brenda Morey
Trust of Edmund L. Murray
Mustaches For Kids
Trust of Louise F. Neely
Craig H. Neilsen Foundation
Estate of Ann M. Nelson
Muriel Neumann
The Newport Foundation
Estate of Jane M. Nicholson
Trust of Florence S. Nilsson
James G. Niven
The Lyla Nsouli Foundation for Children's Brain Cancer Research
Trust of Robert M. Ochs
The Okonite Company
Grace Oughton Cancer Foundation
The Ovarian Cancer Research Fund
The William & Jane Overman Foundation
Eileen and James A. Paduano
Parfums de Coeur Ltd.
Rosalind and Kenneth Pearlman
PepsiCo Foundation, Inc.
Estate of Ann Perkins
Estate of Claude E. Petruzzelli
Pin Down Bladder Cancer
Mr. and Mrs. Jeroen Henk L. Pit
Jean D. Pitcher
Jerry W. Pittman
Plastic Surgery Foundation
Polo Ralph Lauren Corporation
Estate of Elizabeth Polotaye
Trust of Helen M. Price
Estate of Seymour Price
Prudential Financial, Inc.
Robert Pufahl
Purdue Pharma LP
Patricia A. Quick Charitable Trust
Trust of Harriet C. Rath
James N. Rentas 5K Run/Walk
Trust of Anne Ressner
Estate of Walter E. Rex III
The Rice Family Foundation
Louise & Frank Ring
The Ritter Family Foundation
Irene Ritter Foundation
The Andréa Rizzo Dance Therapy Fund
Trust of Lillian Robbins
Mr. and Mrs. Stephen Robert
Robin Hood Foundation
Estate of Sandra Shepard Rodgers
Kenneth C. Rohan
Estate of Nathan Rothstein
Estate of Wilhelmina T. Rouget
Trust of Cecile N. Ruben
Trust of Maurice Ruben
The Selma and Lawrence Ruben Foundation
MRS. ORHAN I. SADIK-KHAN
MRS. EDMOND J. SAFRA
MOISE SAFRA FAMILY
MR. AND MRS. HERBERT E. SAKS
Mara and Ricky Sandler
Trust of Erika Saphier
Trust of Paul C. Sawyer
Trust of Edwin & Grace Sayers
Estate of Christine C. Scanlan
Trusts of Anabel M. Scarborough and Walter L. Scarborough
The Milton Schamach Foundation, Inc.
MR. AND MRS. STEPHEN SCERR
Trust of Edward and Irene Schlosser
Trust of Jennie C. Schneider
Mrs. Silvia A. Schnur
MR. AND MRS. PAUL C. SCHOR IV
Estate of Evelyn Schrank
Trust of Crystal Schull
Estate of Bertha Schulman
The Schultz Foundation
Searle Scholars Program
The Select Equity Group Foundation
The Nina and Ivan Selin Family Foundation
Estate of Sam Selzer
Mr. Frank Senior
Seventh District Association, Inc.
Estate of Gladys N. Severud
The Shanken Family Foundation
Estate of Odette Sharow
Trust of Minnie M. Shaw
Hope Sheridan Foundation
Renee and Irwin Shisiko
Estate of Lillian M. Siemonko
The Grace, George, and Judith Silverburgh Foundation
Trust of Leonard & Ruth Silverman
Leonard and Donna Simon
Trust of Angie S. Skinner
The Gordon H. and Norma Smith Family Foundation
Estate of Robert A. Smith
Estate of Roberta A. Smith
Ms. Beryl Snyder
Society of Interventional Radiology Foundation
Society of New York Workers’ Compensation Bar Association
Roy M. Spear Foundation
The Seth Sprague Educational and Charitable Foundation
Trust of James L. Stackhouse
The Robert Steel Foundation for Pediatric Cancer Research
Trust of Frederick T. Steinberg
The Jeffrey Steiner Family Foundation
Mr. and Mrs. Howard Stern
The Guy M. Stewart Cancer Fund
Estate of Sonia Stolin-Moresco
Trust of May Strang
The Daniel P. Sullivan Clinical Fellowship Fund
Timothy P. Sullivan Charitable Lead Trust
The Greater New York City Affiliate of Susan G. Komen for the Cure
The Paula Takacs Foundation for Sarcoma Research
James R. Tanenbaum and Elizabeth M. Scofield
Frank N. Tedesco
Estate of Ida Tepper
Trust of Annette M. Terdina
Estate of Stella R. Thater
Think Pink Rocks
Thrasher Research Fund
Mr. and Mrs. Carl W. Timpson, Jr.
Estate of Michael Z. Toman
The Robert Mize & Isabella White Trimbly Family Foundation
Mr. Steven Trost
Trust of Irwin C. Unger
United Hospital Fund of New York
United Leukemia Fund Inc.
United Way of New York City
The Lucy & Eleanor S. Upton Charitable Foundation
The Vasey Foundation
Vejay Foundation
Vital Projects Fund, Inc.
Estate of Eleanor B. Vogel
Walk the Walk America, Inc.
Douglas Walker
Estate of Muriel F. Wall
The Washington Post Company
The Bert & Sandra Wasserman Foundation
Marla J. Wasserman
The Scott Weingard Memorial Fund
Mr. and Mrs. Boaz Weinstein
Estate of Elias Weiss
In memory of Marie T. Weiss
John A. Weissenbach and Ann Southworth
Effie Wells-Lonning
Trust of Ida Wharton
Whitehall Foundation
John C. Whitehead
Estate of Ruth Whitfield
William F. and Barbara K. Whitman
The Helen Hay Whitney Foundation
Mr. and Mrs. Frank C. Whittelsey III
The Jesse R. Wike Charitable Trust
Jacqueline and Robert Willens
The David and Ellen Williams Foundation
Kendrick R. Wilson III
Mr. and Mrs. Jon Winkelried
Wooden Nickel Foundation
Trust of Vincent J. Zappolo
Estate of Robert E. Ziegler
Nicholas B. Zoulias
Mr. and Mrs. Jeffrey A. Zucker

$100,000 — $249,999

4LOVE Project
A & P Foundation
Abbott Laboratories
Abbvie Foundation
Acorn Foundation
Peter Bodok
The Louis & Anne Abrams Foundation, Inc.
Jean Ackerman
Mr. and Mrs. Laszlo Adam
Adolph & Ruth Schnurmacher Foundation
The Francis X. Ahern, Sr. Foundation
Roger and Elizabeth Ailes
Daniel G. Alexander
Robert and Elaine Allen
Alliance for Life Sciences & Health
Estate of Lori S. Alper
Mr. and Mrs. Robert I. Alpern
Sheikha Noura Alsheikh
Alzheimer’s Association
The Amaturo Foundation, Inc.
American Federation for Aging Research
Amgen, Inc.
Estate of Maurice Amzalak
Mr. and Mrs. Harold F. Anderson
Richard and Peggy Anderson
Warren and Lillian Anderson
Anonymous
Mr. and Mrs. Jerome V. Ansel
Anthony Brands
The Antonacci Family Foundation
Mr. and Mrs. Rand V. Araskog
Trust of Theodocia D. Arkus
Mr. and Mrs. William J. Armfield IV
Paul Armin Family Foundation
Nicole Sinek Arnbaldoli and Leo Arnbaldoli
Kym S. Arnone
The Aronson Family Foundation
Estate of Bente Arquin
Mary Kay Ash Charitable Foundation
The David R. and Patricia D. Atkinson Foundation
The Isaac and Carol Auerbach Family Foundation
Autism Speaks
Aviesan French National
Mr. and Mrs. Charles Ayres
B*CRUED
Trust of Maureen E. Bacon
Dr. Joseph J. Bailey
Elliott A. Baines
The Baird Family Fund
Gail L. Baird Family Foundation
The Solomon R. and Rebecca D. Baker Foundation
David M. and Barbara Baldwin Foundation Inc.
Ariela and Mendel Balk
Estate of David B. Ballard
Estate of Harold F. Bannister
Mr. and Mrs. Robert L. Barbanell
Trust of James R. Barber
Barish Family Foundation

65
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Grace M. Barry
Estate of Kaethe F. Barry
Estate of Patricia A. Barry
Trust of Eileen L. Batten
Trust of Joyce A. Battle
The Modestus Bauer Foundation
Lynn B. Bayard
Be the Difference Foundation
Estate of Thelma Beatty
Trust of John A. Beatty
Mr. and Mrs. Edmund Becker
Estate of Charles R. Beechler
Trust of Kathe Begeest
Estate of Robert D. Bennett
Corinne Berezuk and Michael Stieber
Trust of Isidore Bergner
Mr. Bernard S. Berkowitz
Joan and James Berkowitz Fund
Estate of Tony P. Bernabich
The Bill Bernbach Foundation
Steffi and Robert Berne
Mrs. Louis Bernstein
Jacqueline Bikoff
Estate of Margaret L. Bingman
Biomet
Trust of C. June Bisplinghoff
BJ’s Charitable Foundation
The Blackstone Charitable Foundation
Bladder Cancer Advocacy Network
Trust of Raymond Blake
Blaker Family Fund
Hector Payares Blanco
Bill Blass Licensing Company, Inc.
Madeline and Alan S. Blinder
Ambassador and Mrs. Alan J. Blinken
Mr. and Mrs. James A. Block
Estate of Vivian K. Blonder
The Walter & Adi Blum Foundation, Inc.
Trust of Eli Blumenfeld
Harold and Adele Blumenkrantz
Estate of Simon P. Blustone
D. Dixon Boardman
Bruce Bocina
Estate of Marti A. Boden
Estate of Alan A. Bohlinger
Estate of Marjorie R. Boselly
The Boston Foundation
Alan F. Bovee
William R. Boyle
Estate of Mary C. Brabson
Estate of Elsie L. Bradford
The Bradshaw Family
Brahman Capital
Brain Tumor Funders’ Collaborative
Anna M. and Mark R. Brann
Mr. and Mrs. Henry R. Breck
Milton Brenner
Estate of Mae Bridewell
Trust of Marie H. Brock
The Broder Family Foundation, Inc.
Estate of Edna Brodie
Randall Brooks
Ms. Betsy Levine-Brown and Mr. Marc Brown
Carl and Nickey Brown
David A. and Merle L. Brown
Brown Helicopter, Inc.
Trust of Ruth Ann Brown
Estate of William A. Brown, Sr.
The Brownington Foundation
Mr. and Mrs. Norman Brownstein
Estate of Vernon Brunelle
Elizabeth Bucher
The Peter & Carmen Lucia Buck Foundation
Melva Bucksbaum and the Robert I. Goldman Foundation
Janna Bullock
Trust of Florence Bunn
Mr. and Mrs. Franz H. Burda
Estate of Lillian Burg
Estate of Edith B. Burger
Mrs. Coleman P. Burke
Estate of Louise V. Burnett
Janet Burros Memorial Foundation
Mr. and Mrs. Harold Busch
Estate of John D. Bush
Mr. and Mrs. Jonathan J. Bush
The Paul Nabil Bustany Foundation
Gilbert and Ildiko Butler Family Foundation, Inc.
Estate of Ruth J. Butterworth
Estate of Lillian A. Byman
Mr. and Mrs. Donald G. Calder
Mr. and Mrs. Bruce L. Calhoun
Trust of Marilyn Campbell
Cancer Research & Treatment Fund
Leah Rush Cann
James A. Cannon
Estate of Edward A. Cantor
Trust of Jacqueline Carrnick
Mr. and Mrs. Edmund M. Carpenter
Mr. and Mrs. Warren E. Carpenter III
Estate of Eugene Carrara
Estate of William K. Carson
Mr. and Mrs. William M. Carson
Estate of Colon B. Carter
Trust of Winifred T. Carter
Estate of Elise Cartotto
Joan (Perkowski) Cashin Foundation
Casual Male Corp.
The Cayuga Foundation
Estate of Charlotte A. Celian
Mr. and Mrs. E. Val Cerutti
Trust of George F. Chagnon
Trust of Henry D. Chaikin
Dr. Kalpana Chakravartty
Chanel, Inc.
Margaret Anne Chappell
Mr. and Mrs. Bernard T. Chausse
Estate of Camille Chericone
Child Neurology Foundation
Childhood Brain Tumor Foundation
The Children’s Brain Tumor Foundation
Children’s Neuroblastoma Cancer Foundation
The Francis and Miranda Childress Foundation
The Jane Coffin Childs Memorial Fund for Medical Research
Chordoma Foundation
Estate of Selma Chyatt
William Joseph Ciliberti
Judith Ann Cion Revocable Trust
Estate of Piera Ciriello
Amanda Styles Cirelli Foundation for Pediatric Cancer Research
The Anne L. and George H. Clapp Trust
Estate of Lyman W. Clardy
Estate of Ina Clarke
Estate of Mary M. Cleary
Cleveland Clinic Health System
CLL Global Research Foundation
The Coca-Cola Company
Mr. and Mrs. Laurence W. Cohen
Mr. and Mrs. Charles Payson Coleman III
Clarence L. Coleman Jr. and Lillian S. Coleman Foundation
James J. Coleman, Jr.
Paul Jackson Coleman
Estate of Gertrude T. Coles
Robert and Maryann Collin
Estate of Arthur R. Collins
Estate of Lila V. Collins
The Colon Cancer Foundation
Mr. and Mrs. Alexius Conroy
Consolidated Edison Company of New York
Dudley P. Cook
Mr. and Mrs. Errol M. Cook
Mrs. William B. Cook
Cooley’s Anemia Foundation
Mr. and Mrs. E. Gerald Cooper
Estate of Morris Coppersmith
Estate of G. R. Couch
Courtesy Associates, Inc.
Anne Cox Chambers Foundation
Estate of Edith C. Cox
Trust of Burton L. Craig, Jr.
Trust of Franklin C. Craig
W Michael and Lois Craig
Trust of Louise Crites
The Crown Family
Bruce Crystal
Cure Alzheimer’s Fund
Mr. and Mrs. James F. Curtis III
Cusa Realty, LLC
Custom Design Communications, Inc.
William J. Cwenn
Mrs. Charles A. Dana, Jr.
Estate of Richard Daniels
The Gloria and Sidney Danziger Foundation, Inc.
Estate of Hannah Danziger
The E. S. F. Das Foundation
Guy and Sally Davidson
Estate of Hazel Davidson
Mr. and Mrs. Scott E. Davidson
Trust of Jane Davies
<table>
<thead>
<tr>
<th>Name and Organization Name</th>
<th>Name and Organization Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Ellen and Gary Davis Foundation</td>
<td>Mr. and Mrs. Alfonso Fanjul, Jr.</td>
</tr>
<tr>
<td>Roxana V. Dawson</td>
<td>Estate of Marion E. Feigenbaum</td>
</tr>
<tr>
<td>Estate of Karin D. de Chellis</td>
<td>Gretchen V. and Samuel M. Feldman</td>
</tr>
<tr>
<td>Estate of Jean Decker</td>
<td>The Corinne Feller Memorial Fund</td>
</tr>
<tr>
<td>Estate of Liborio DeFilippis</td>
<td>Trust of Robert I. Fendrich</td>
</tr>
<tr>
<td>The Lawrence and Florence DeGeorge Charitable Trust</td>
<td>Roger W. Ferguson, Jr.</td>
</tr>
<tr>
<td>Lynn DeGregorio</td>
<td>Trust of Thelma F. Fernandez</td>
</tr>
<tr>
<td>Estate of Katherine C. DeHaan Goff</td>
<td>Fetter Institute</td>
</tr>
<tr>
<td>Anthony Del Bove</td>
<td>Trust of Lydia K. Fiedler</td>
</tr>
<tr>
<td>Estate of Helen Demetriades</td>
<td>Gloria S. Fine</td>
</tr>
<tr>
<td>Mr. and Mrs. Anthony Diaco</td>
<td>First Eagle Investment Management</td>
</tr>
<tr>
<td>The Miriam &amp; Arthur Diamond Charitable Trust</td>
<td>Randee and Howard Fischer</td>
</tr>
<tr>
<td>The Ernst &amp; Jeannette Dicker Foundation</td>
<td>Estate of James K. Fisher</td>
</tr>
<tr>
<td>Estate of Margaret DiDonato</td>
<td>Estate of Nellie G. Fishman</td>
</tr>
<tr>
<td>Estate of Richard I. Diennon</td>
<td>Estate of William and Frederica Fissell</td>
</tr>
<tr>
<td>Discavage Family Foundation</td>
<td>Trust of Loretta B. Fitzgerald</td>
</tr>
<tr>
<td>Mr. and Mrs. Daniel L. Doctoroff</td>
<td>Mr. and Mrs. Thomas M. Fitzgerald III</td>
</tr>
<tr>
<td>Oliver S. &amp; Jennie R. Donaldson Charitable Trust</td>
<td>The Francis Florio Fund of the New York Community Trust</td>
</tr>
<tr>
<td>Estate of Maurice A. Donovan</td>
<td>Steve Forbes</td>
</tr>
<tr>
<td>John R. Doss</td>
<td>The Mary Alice Fortin Foundation</td>
</tr>
<tr>
<td>Percy S. Douglas</td>
<td>Richard N. Foster</td>
</tr>
<tr>
<td>Susie M. Downing</td>
<td>Trust of Aida A. Foti</td>
</tr>
<tr>
<td>Mr. and Mrs. Frank P. Doyle</td>
<td>Four Seasons Hotel – New York</td>
</tr>
<tr>
<td>Trust of Max Drechsler</td>
<td>The Fan Fox and Leslie R. Samuels Foundation, Inc.</td>
</tr>
<tr>
<td>Dreyer’s Grand Ice Cream, Inc.</td>
<td>Estate of Thomas R. Foy</td>
</tr>
<tr>
<td>Jane Clausen Drorbaugh</td>
<td>Claire and Meyer W. Frank and Leann Frank</td>
</tr>
<tr>
<td>Dr. Scholl Foundation</td>
<td>Charitable Foundation</td>
</tr>
<tr>
<td>Dr. Jeffrey Duban</td>
<td>Trust of Irene R. Frank</td>
</tr>
<tr>
<td>Trust of Anne Duerden</td>
<td>Charles A. Frueauff Foundation</td>
</tr>
<tr>
<td>Trust of Patricia P. Duffy</td>
<td>Helen Frankenthaler Foundation</td>
</tr>
<tr>
<td>Estate of Doris M. Dunham</td>
<td>Estate of Katherine Freeman</td>
</tr>
<tr>
<td>Margaret H. Dunwiddie</td>
<td>Frey Family Foundation, Inc.</td>
</tr>
<tr>
<td>The Durst Organization, Inc.</td>
<td>Zoltan Fried</td>
</tr>
<tr>
<td>The Edelman Family</td>
<td>Susan and Fred Friedman</td>
</tr>
<tr>
<td>Doris M. Edwards</td>
<td>Estate of Joseph F. Fursa, Jr.</td>
</tr>
<tr>
<td>E. E. Cruz Company</td>
<td>Mr. and Mrs. Thomas J. Gahan</td>
</tr>
<tr>
<td>Mr. and Mrs. Blair W. Effron</td>
<td>Trust of Ralph W. Gaines</td>
</tr>
<tr>
<td>Trust of Bertram Ehrlich</td>
<td>Estate of Anne Gallagher</td>
</tr>
<tr>
<td>Trust of Raymond Ehrlich</td>
<td>Anita C. Garoppolo</td>
</tr>
<tr>
<td>Estate of Elinor Ehrman</td>
<td>Mr. and Mrs. Julius R. Gaudio</td>
</tr>
<tr>
<td>Estate of Estelle Eisenstat</td>
<td>GC for a Cure 5k Run/Walk</td>
</tr>
<tr>
<td>Mr. and Mrs. Frederick Elghanian</td>
<td>Bruce G. Geary Foundation</td>
</tr>
<tr>
<td>Martin Elk League for Cancer Research</td>
<td>Trust of Louis C. Geiger</td>
</tr>
<tr>
<td>Trust of Arnold B. and Joan S. Elkind</td>
<td>Trust of William G. Genner, Sr.</td>
</tr>
<tr>
<td>Mr. and Mrs. Richard S. Emmet</td>
<td>Kara and Peter Georgiopoulos</td>
</tr>
<tr>
<td>Andrew J. Entwistle</td>
<td>Estate of Jacques A. Gerard</td>
</tr>
<tr>
<td>Estate of Lillian Epps</td>
<td>Robert &amp; Sylvia Gergen</td>
</tr>
<tr>
<td>Mr. and Mrs. Christopher Errico</td>
<td>Estate of Charles J. Gerhart</td>
</tr>
<tr>
<td>Rafael Etzion</td>
<td>Panayotis Gerolymatos</td>
</tr>
<tr>
<td>The Charles Evans Foundation</td>
<td>The Patrick A. Gerschel Foundation</td>
</tr>
<tr>
<td>Edward P. Evans Foundation</td>
<td>Trust of Alda Getti</td>
</tr>
<tr>
<td>Estate of Eugene M. Evans, Jr.</td>
<td>Estate of Theresa A. Ghiringhello</td>
</tr>
<tr>
<td>The Evslin Family Foundation</td>
<td>Marlene and Alan Gilbert</td>
</tr>
<tr>
<td>Trust of James D. Ezzell</td>
<td>Estate of Rosemarie M. Gilman</td>
</tr>
<tr>
<td>Family Reach Foundation</td>
<td>Mrs. Bruce A. Gimbel</td>
</tr>
<tr>
<td>Fanconi Anemia Research Fund</td>
<td>Trust of Adele Ginsburg</td>
</tr>
<tr>
<td>Mr. and Mrs. William H. Girvan</td>
<td>The Harvey S. Gitlin Family Foundation</td>
</tr>
<tr>
<td>Estate of Grace E. Glenn</td>
<td>Glenwood Management Corporation</td>
</tr>
<tr>
<td>Trust of Glenn R. Gobble</td>
<td>Trust of Adele Ginsburg</td>
</tr>
<tr>
<td>Christina and Peter Gold</td>
<td>Estate of Elizabeth W. Hahn</td>
</tr>
<tr>
<td>Mr. and Mrs. Bradley Goldberg</td>
<td>Estate of Mazie J. Hall</td>
</tr>
<tr>
<td>Leslie H. Goldberg</td>
<td>Estate of Helen Sue Hameetman</td>
</tr>
</tbody>
</table>
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Jeanne G. Hamilton and Lawson W. Hamilton, Jr. Family Foundation, Inc.
Milton and Miriam Handler Foundation
Estate of Stanley E. Handman
Trust of Robert Hanson
Estate of Marion K. Hardwicke
Estate of Mary Jane Harrington
Harrington Discovery Institute
The Mary W. Harriman Foundation
Leonard B. Hart
Laura Hartenbaum Breast Cancer Foundation
Mr. and Mrs. William R. Hartong
Have A Chance, Inc.
Trust of Peter J. Hayes
Haymakers for Hope
Morris A. Hazan Family Foundation
HCCF Foundation
Mr. and Mrs. Andrew P. Heaney
Trust of Lonie G. Hearn
The Per and Astrid Heidenreich Family Foundation
Trust of Shirley S. Heiligmam
Mr. and Mrs. Robert M. Hendrickson
Mr. and Mrs. John Hennessy
The Maxine R. and Richard L. Henry Trust
Estate of Robert Hensel, Jr.
Carolina Herrera, Ltd.
Trust of Leon Hershaf
Ms. Marlene Hess and Mr. Jim Zirin
Trust of Marie Hesselbach
Heymann-Wolf Foundation
Estate of Manny Hilfman
Hillenbrand Family Foundation
Mrs. John S. Hilson
The Mark Hindy Charitable Foundation
Trust of Myfanwy Hinkle
Estate of Vladimir Hladik
Estate of Edward B. Hodge
Estate of Marion Hoffman
Estate of Ruth M. Hoffman
Trust of Steward B. Hoffman, Sr.
Hoffman-La Roche Inc.
Deborah H. and Sigmar K. Hofmann
Hope V. Hofmann
Mrs. Carolyn T. Holden
Trust of Burt Holtzman
Howard and Carol Holtzmann
Estate of Margaret Hooghuis
Estate of Herman L. Hoops
Trust of Anita S. Horbacz
Alfred Samson Hou
Robert Howard Family Foundation
Estate of Frank Huber
Nancy Hughes
Humanscale Corporation
Estate of Edna Hunt
Carol Hunter
Constance D. Hunter
Estate of Edith M. Hunter
James B. Hunter
Hyundai Motor America
I Back Jack Foundation, Inc.
Mr. and Mrs. David W. Ichel
Estate of Priscilla T. Iden
Inamed Corporation
Incyte Corporation
Ingersoll Rand Company
Mr. and Mrs. William H. Ingram
The Interpublic Group of Companies
Irish Society of Medical Oncology
IT Figures LLC
J. P. Wish Fund
Jacobus-Iacobucci Foundation
Estate of Harold F. Jaeger
Mr. and Mrs. Stanley R. Jaffe
Thomas Jaffe
James Family Foundation
JDRF
Trust of Ann E. Jennings
Richard H. Jenrette
The Jewish Communal Fund
Mr. and Mrs. Peter James Johnson, Jr.
The Samuel C. Johnson Trust
J.P. Wish Fund
The Kahn Charitable Foundation
Trust of Frank J. Kahn
Trust of Nina M. Kaiser
Kaleidoscope of Hope Foundation
Jane Kalmus
Harry P. Kamen Family Foundation
Mr. and Mrs. Daniel B. Kamensky
Trust of Mildred Kaminsky
Canarek Family Foundation
Estate of Lee L. Kanarian
Estate of Eleanor Kane
Mr. and Mrs. William Kane
Estate of Bernard Kantor
Steve and Meghan Kanzer
Estate of Irvin L. Kaplan
Marie H. Karger
The Karma Foundation
Trust of Jerry Katz
Trust of Toby Katz
Edward M. Kaufmann
Trust of John Kaufmann, Jr.
Trust of Ralph W. Kaufmann
Mr. and Mrs. Robert M. Kavner
Carl Michael Kawaja and Gwendolyn N. Holcombe
Thomas F. Kearns
Charles L. Keith & Clara Miller Foundation
Mr. and Mrs. Brian G. Kelly
Estate of Ruth C. Kelly
Mrs. Ann Kelman and the late Dr. Charles D. Kelman
Eleanor and Michael Kennedy
Peter Kenner Family Fund
J. Kevin Kenny
Kensico Capital Management
John A. Kent
Estate of Herman Kerner
The Glenn D. Kesselhaut Children’s Joy Fund
Estate of Mary F. Kessler
Mr. and Mrs. Peter A. Kessler
Coyla E. Ketchy
The Kettering Family Foundation
Estate of Henri Khouri
Doris and Floyd Kimmel Foundation
The King Family Charitable Lead Trust
Mr. James W. Kinnear II
Patricia A. Kirby
Mr. and Mrs. James M. Klausmann
David L. Klein, Jr. Foundation
Robert D. Klemme
The Esther and Joseph Klingenstein Fund
Mr. and Mrs. Steven B. Klinsky
Fernand Koch
Estate of Gale K. Kokubu
Mrs. Mitzi Koo
The Koppelman Family Foundation
Robert A. Kotick
Mr. and Mrs. Bruce S. Kovner
Mr. Kenneth Kret
Mr. and Mrs. Jerome I. Kroll
Trust of Grace E. Kruse
KVFF Fund
Dina Hubell and the Labkon Family
Mrs. Thomas G. Labrecque
Estate of Sidney J. Lacher
Estate of Schubert L. Lamb
Estate of Marvdene B. LaMonica
The Edward & Kinga Lampert Foundation
Emma Landau
Mr. and Mrs. Barry Lang
Estate of Annie Langen
Estate of Anne Lanigen
J. Clair and Pamela Lanning
Dr. Gerald D. Laubach
Mrs. Lois H. Lazaro
Trust of Edwin S. Lee, Jr.
Mr. and Mrs. Thomas V. Leeds
Gary Leet
The Leikofsky Family Foundation
Lehman Brothers Inc.
Karen and James Lehrburger
Mr. and Mrs. Lewis E. Lehrman
Trust of Martha B. Leigh
Estate of Helen Lesniewski
The Leukemia & Lymphoma Society
Laurence W. Levine Foundation
Estate of Dina Levinsky
Elvire Levy
Estate of Erna T. Lewine
The Marvin and Kay Lichtman Foundation
Mr. and Mrs. Richard Lightburn
Linda Lipay
Trust of Wilhelmina I. Lipfert
Ira A. Lipman
Lisa’s Heart Kids’ Cancer Research Fund
The Harold I. & Faye B. Liss Foundation
Mr. and Mrs. Martin Liss
Linda Litwack
The Lucius N. Littauer Foundation
Live, Love, Laugh Foundation
Estate of Dina Livolsi
Demarest Lloyd, Jr. Foundation
Jeanette and Peter Loeb
Stephanie and James Loeffler
Long Island League to Abolish Cancer
Estate of Margaret S. Longwell
Estate of Anthony Lopez
Mr. and Mrs. José Luis Los Arcos
Losritto Family
Milton Lowenstein
James J. and Marianne B. Lowrey
The Lucerne Foundation
Cynthia and Dan Luquin
Eric and Susan Luse
Ronald S. Lux
Mr. and Mrs. Alexander P. Lynch
Trust of John F. Lynch
Estate of Kathleen E. Lynch
Estate of Charles S. Lyons
Estate of Melvin E. Lyons
Josiah Macy, Jr. Foundation
The Arthur and Holly Magill Foundation
John Magnier
The Maguy Foundation
The Arthur I. and Susan Maier Foundation
Estate of Margaret E. Maihl
Estate of Margaret H. Mairs
Maite Aquino Memorial Fund
Estate of Mariette P. C. Major
Herbert J. Maletz
Estate of Irving and Harriet Malitson
Peter J. Malkin
Elissa Caterfino Mandel
Karen G. Mandelbaum
Estate of Harry Marder
Estate of Ida Mae Margolis
Trust of Carlton G. Marie
Edward J. Marino
Jerome S. and Maria Markowitz
Zvi and Linda Markowitz
Estate of Benjamin Marmer
The Christina & Paul Martin Foundation
Mr. and Mrs. Roman Martinez IV
Dorothy Marx
Jo-Ann Marx, MD
Estate of Johanna Marx
Estate of Rita B. Masse
James Mathos
The Hale Matthews Foundation
Trust of Walter J. Matthews
The Matt's Promise Foundation
Maverick Capital Charities
Mr. and Mrs. Hamish Maxwell
Maynard Childhood Cancer Foundation
Mr. Michael Mazzucca
Max Mara USA, Inc.
Estate of Ralph L. McBean
Estate of Ann C. McBride
Estate of Donald J. McCarraker
Estate of John C. McDanielis
Mr. and Mrs. Jeffrey A. McDermott
McDonald Financial Group
Lee McDonald
Ralph McDonough
The Dextra Baldwin McGonagle Foundation
McKeen Fund
Mr. and Mrs. Edward B. McKeough
The McKeen Endowment Fund for Neuroscience
Estate of Geoffrey McLaughlin
Estate of Mary E. McMaster
Mr. and Mrs. David B. McQueary
The Meckler Foundation
Melanoma Research Foundation
The Melville Foundation
Mr. and Mrs. Prakash Melwani
Estate of Dorris M. Mendelsohn
Estate of Irving M. Mendelson
Estate of Lorraine Mensing
Julia and Gilbert Merrill Foundation
Estate of Amy Joan Meskin
Trust of Ruth W. Metcalfe
Mr. and Mrs. Frank A. Metz, Jr.
Estate of Abby E. Meyer
Estate of Ursula Meyer
The Emanu E. Micalet Foundation
Mrs. Sidney Michael
Trust of William M. Michaelson
Trust of Florence B. Mickels
Cristine Meredith Miele Foundation
The Mike and Steve Foundation
Elaine P. Miles
Eleanor F. Miley
Carolyn Rosen Miller Family Foundation
Mr. and Mrs. Donald K. Miller
Mr. and Mrs. Larry J. Miller
Mr. and Mrs. Matthew Miller
Mr. and Mrs. Richard A. Miller
Mrs. Mary E. S. Milligan
Monroe & Judith Milstein Philanthropic Fund
Estate of Dorothy B. Minard
Allen Minsky
Melissa and Robert Mittman
Leslie M. Modell
Estate of Catherine Mohan
Estate of Irene Mokrzycki
Trust of Celestine Elizabeth Moloney
Estate of William Monaghan
Pauline M. Monte Leone
Arthur R. Montgomery
John and Hee-Jung Moon
Estate of Pauline Moor
Mr. and Mrs. Charles V. Moore
Estate of Percy W. Moore
Tom & Judy Moore Foundation
The Garrett and Mary Moran Trust
Estate of Barbara B. Morgan
Melissa and Chappy Morris
Alfred L. and Annette S. Morse Foundation
Ken and Linda Mortenson
Mr. and Mrs. George K. Moss
Manuel and Mercedes Mosteiro
Lisa and Marcelo Mottesi
Virginia M. Mueller
Estate of Irving Mulde
Mrs. Sandy Mulligan
Mr. and Mrs. Thomas W. Murphy II
Ernest Muth
Edith L. Nathanson
The National Genetics Foundation, Inc.
NBC Universal
Estate of Leslie A. Nelkin
Trust of Jerome Nerenberg
New York City District Council of Carpenters Relief and Charity Fund
New York State Health Foundation
Gerald L. Nichols and Jacqueline W. Nichols Foundation
Joseph P. Noonan
Trust of Robert F. Novak
The Nussbaum/Kuhn Foundation
NYS Fraternal Order of Police Foundation
The Michael A. O’Bannon Foundation
Estate of Ernestine A. O’Connell
Mr. and Mrs. Jeremiah O’Connor
Trust of Emily C. O’Grady
Dura and Tim O’Hara
Estate of Grace O’Hare
The Oceanic Heritage Foundation
Mr. and Mrs. Wm. Montague Oeste, Jr.
George L. Ohrstrom, Jr. Foundation
Oki Data Americas, Inc.
Harold N. Openshaw, Jr.
Mr. and Mrs. John D. Opie
Optiscan
Estate of Elaine Orbach
Otis Elevator Company
Mr. and Mrs. Gunnar S Overstrom III
Mr. and Mrs. Neil Padron
Pam’s Pals Inc.
Daniel P. and Nancy C. Padian Family Foundation
Mr. and Mrs. Jordan M. Pantzer
The Parnassus Foundation
Rosalie Pataro
Trust of Edith Pattison
Estate of Herman L. Paul, Jr.
Richard S. Peckler
Pediatric Brain Tumor Foundation
Pells-Mayton Foundation
Trust of James A. Pemberton
Mrs. Richard T. Perkin
Mort Perlroth
Lisa and Richard Perry
The Pershing Square Foundation
Estate of Ruth Peterson
Estate of Frederick D. Petrie
The Pew Charitable Trusts
Mr. Donald Pfanz
Samantha and Ernst Pfenninger
Trust of Peter H. Pfugh
Mr. and Mrs. Francois de Saint Phalle
Phelps Family Foundation
Estate of Edmund Piasecki
Trust of Charles V. Pickup
Estate of Irene Pickup
Alicia and Corey Pinkston
DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Mr. Alessandro Pinto
Mr. and Mrs. Roy R. Plum
Estate of Beatrice Pockrass
Estate of John E. Polek
Mr. and Mrs. Gerard Pompilio
The Ponagansett Foundation, Inc.
Janis Z. Porch
Trust of Ann C. Porterfield
Estate of Edna G. Potter
Estate of John A. Powers
John and Jane Powers Foundation
Trust of Ruth S. Prall
Precision Medicine Research Associates
Prevent Cancer Foundation
Rita Price
The Procter & Gamble Company
Estate of Ardyss M. and Harold I. Proctor
Project Ladybug, Inc.
The William H. Pruoff Foundation
Trust of Raymond F. Prussing
Dr. and Mrs. Mark Ptashne
Richard I. Purnell Fund
Estate of Richard I. Purnell
Bambi Lyman Putnam
Trust of Anna Marie Putti
Roselyn Flum Radcliffe
Trust of Samuel J. Radcliffe, Jr.
Stewart Rahr
Trust of Betty Raiff
Richard E. Rainwater
Mary L. Ralph Philanthropic Fund
Mr. and Mrs. Edward A. Rankin
Theodore A. Rapp Foundation
John H. Rassweiler
Abigail T. Reardon
Estate of Phyllis E. Redmerski
Elonore Reed
Estate of Martha Cuneo Reed
Samuel P. Reed
Compton Rees, Jr.
Odette Regine Foundation
The Beatrice Renfield Foundation
Mr. and Mrs. Ira L. Bennert
Olivier and Yosun Reza
The Audrey Rheinstorm and Anne Blevins Fund
Estate of Roland S. Rhode
Judy Rhulen and Family
Martin Rich
Anne S. Richardson Fund
Trust of A. Leslie Richardson
Dee Dee Ricks
Trust of Margaret L. Rigby
Estate of Harry Rinehimer
Estate of Elizabeth M. Ringo
Trust of Victoria Rinius
The Fannie E. Rippel Foundation
Estate of Norma Risman
Abigail Rittmeyer
The RMF Family Fund, Inc.
Bernard and Elaine Roberts
Estate of Floyd B. Roberts
Trust of Irene M. Roberts
Vivien Rock
Rodale, Inc.
Estate of Maria Rolfe
Sheldon Rose
Taryn Rose International
Estate of Sylvia Rosenberg
Trust of Ilisa Rosenblum
Trust of Evelyn Rosenstein
Jeffrey Rosenzweig Foundation for Pancreatic Cancer Research
Leo Rosner Foundation
Mrs. Howard L. Ross
Estate of Sylvia Ross
Estate of Eva L. Rothberg
Philip and Marcia Rothblum Foundation
Mr. and Mrs. Eric A. Rothfeld
Estate of Geraldine E. Rove
Denise Rover
Fra and Jeff Rowbottom
Mr. and Mrs. Charles Royce
Estate of Pearl Rubin
Mr. and Mrs. Mitchell E. Rudin
Estate of Maria Stella Ruggirello
Estate of Katherine L. Rummel
The Russell Family
Estate of Roberta Russo
Estate of Eileen B. Ruthrauff
The Derald H. Ruttenberg Foundation
Trust of Anne I. Ryan
Andrew Sabin Family Foundation
Martin Sabowitz and Muriel Goldrich
The Saibel Foundation
Estate of V. Edward Salamon
Mr. and Mrs. Eugene L. Salem
Mr. and Mrs. William R. Salomon
Trust of Rose K. Salzwes
Trust of Sidney Samuels
Henry Sanborn
Estate of Andrew D. Sanders
The Sandler Family
Nina and Julian Sandler Charitable Fund
Lt. Colonel (Ret.) Joseph Santa Barbara
Mrs. Barbara Santangelo
The Sarah I. Schieffelin Residyuar Trust
The Sass Foundation for Medical Research
The Saw Island Foundation
Estate of Ida M. Scagliarini
Scalamandre Silks
Didi and Oscar S. Schafer
Peter L. Schaffer
Estate of Richard Scharff
Estate of Sylvia Schatzman
The LeRoy Scehter Foundation
Bill Scherman and Holly Joyner
Pasco L. Schiavo
Estate of Josephine L. Schiff
Estate of Billie Schneider
Mr. and Mrs. Robert Schneider
The Schneider-Kaufmann Foundation, Inc.
Trust of Edward K. Schnepp
Trust of Lola Schug
Estate of Harold B. Schwartz
Theodore G. Schwartz Family Foundation
Estate of Rosalind Schwartzbach
Trust of Paul J. Schwarz
Mrs. Arline Schwarzman
Mr. and Mrs. Jeffrey E. Schwendeman
Trust of Robert E. Schwenk
Mr. and Mrs. John W. Scully
Estate of Jewel C. Seab
Secunda Family Foundation
The Jean & Charles Segal Foundation
Janet Prindle Seidler Foundation
Mr. David Sekiguchi
Rena Selden
The Maryam and Hervey Seley Foundation
Rosemary Selky
R. B. Sellers Foundation
Dominique Senequier
Sephardic Hospital Fund – Medstar
The Jacqueline Seroussi Memorial Foundation
L. J. Sevin
Harold Shames
The Shana Alexander Charitable Foundation
Estate of Reuben Shane
Estate of Saul Shapiro
The Sharma Foundation
Trust of Margaret S. Sharp
Estate of Bernice Baruch Shawl
Estate of Alice Sherwin
The Shevell Family
Estate of Leo A. Shifrin, MD
Mr. and Mrs. Stanley B. Shopkorn
Mr. and Mrs. William Shulevitz
Mr. and Mrs. Steven J. Sidewater
Muriel F. Siebert Foundation
Estate of Ruth Siegmann
Estate of Mary Siekert
Trust of Walter Silberfarb
Mr. and Mrs. Robert H. Silver
The Slomo & Cindy Silvian Foundation
The Seymour Simon Charitable Trust
Marilyn M. Simpson Charitable Trust
Simpson Thacher & Bartlett Trust
Trust of Marie A. Sinclair
Trust of Otto K. & Harriet J. Singer
Estate of Shirley Singer
Estate of Madeline Sisak
Estate of Evelyn M. Skolnick
SL 2005 Family Trust
The Alan G. Slifka Foundation
Estate of Alvin F. Sloan
Dr. and Mrs. Bernard E. Small
Suse Smetana
Louis and Dora Smith Foundation, Inc.
The Randall and Kathryn Smith Foundation
Mr. Robert J. Smith
Estate of Woodrow Q. Smith
Estate of Dorothy Smolen
Catherine M. Smolich
Trust of Robert J. Smutny
Mr. and Mrs. Jay T. Snyder
Valerie L. Sodano
The Harry & Estelle Soicher Foundation
Trust of Robert Solnick
Therese and Marshall Sonenshine
Professor and Mrs. C. Alan Soons
Estate of Sharon Sorok
Soros Fund Charitable Foundation
Sotheby's
The Honorable Joyce L. Sparrow
Mr. and Mrs. Richard A. Spelke
Trust of Henry Spenadel
Estate of Regina W. Spence
Alvira R. Spencer
Estate of DeAnne Spencer
Estate of Agnes Spillmer
The St. Giles Foundation
Ronald Stafford Cancer Support Foundation, Inc.
Staten Island Yacht Sales, Inc.
Mr. and Mrs. Robert A. Staub
Esta Eiger Stecher
Mr. and Mrs. Edward C. Steele
Estate of Sanford L. Steelman
Estate of Dennis Stein
The Fred & Sharon Stein Foundation
Mrs. Nancy Steinfeld
The Ernest E. Stempel Foundation
The Aaron and Betty Lee Stern Foundation
Estate of Irene Stern
Estate of Winona H. Stevens
J. McLain Stewart
Estate of Rebecca Stohl
Mr. and Mrs. Stuart P. Stoller
Mr. and Mrs. Norman L. Stone
Mr. and Mrs. Robert A. Staub
Estate of Shirley F. Watkins
Elizabeth T. Wassmundt
Mr. and Mrs. Bruce Wasserstein
Warren/Soden/Hopkins Family Foundation
Estate of Shirley I. Warner
Estate of Frances M. Wanek
Mr. and Mrs. Paul D. Walsh
Estate of Lillie M. Waldon
The Paul E. and Mary Wagner Trust
Estate of Robert P. Thome
Trust of Robert W. and Pauline Z. Thompson
Trust of Vernon Thompson
The Vernon F. & Mae E. Thompson Charitable Foundation
Thrill Hill Productions
Tiffany & Co.
Mr. and Mrs. Alexander Tisch
Estate of Margaret R. Tomas
Estate of Milton Topolsky
Estate of John J. Tormey
The Tortuga Foundation
Estate of Virginia M. Toth
Trust of Angelina Ann Tovar
Mr. and Mrs. David C. Tracey
Jill Tracey
Estate of Rita L. Tracey
Trust of Helen A. Trahin
Trust of Dorothy B. Traufeld
Beatrice Travis-Cole
The Bud Traynor Memorial Fund, Inc.
The W. James & Jane K. Truettner Foundation
Estate of Ina Tuckman
Estate of R. Read Tull
Lucien L. and Shirley Turk
John J. Twomey
Ahavas Tzdeek Foundation
David V. Uhlein, Sr.
Elaine L. Ulrich
The Unger Family Foundation, Inc.
Mr. and Mrs. Mark D. Unger
The Valley Foundation
Valley of the Sun United Way
The van Ameringen Foundation
Estate of June A. Vanderpool
Jonathan and Sarah Vanica (GS Gives)
The Vanneck-Bailey Foundation
Varhegyi Foundation
The Varnum DeRose Trust
Dr. Terry G. Vavra and Linda F. Vavra
In memory of Madeline C. Verducci
Estate of Andrea M. Vernick
The Victoria's Smile Foundation
Trust of Eva Vida
The Family of Maria Elena Villanueva
Estate of Dorothy Voelker
Trust of Anna L. Vogel
Estate of Gertrude Vogel
Voices Against Brain Cancer Foundation
Ralph W. Voit
Trust of Beverly Wachtel
Wachtell, Lipton, Rosen & Katz
The Paul E. and Mary Wagner Trust
Estate of Lillie M. Waldon
Mr. and Mrs. Paul D. Walsh
Estate of Frances M. Wanek
Estate of Shirley L. Warner
Warren/Soden/Hopkins Family Foundation
Mr. and Mrs. Bruce Wasserstein
Elizabeth T. Wassmundt
Estate of Shirley F. Watkins
Mr. and Mrs. Peter Webster
Mr. and Mrs. Bradford G. Weekes III
Mr. and Mrs. John G. Weiger
Trust of Gertrude H. Weiler
Mrs. John L. Weinberg
Marc S. Weinberger
Danny M. Weinheim
The Isak & Rose Weinman Foundation, Inc.
Estate of Louis Weinstock
Mr. and Mrs. Michael Weisberg
Andrew and Ronnie Weiss
Estate of Gertrude Weiss
Trust of Gertrude Weilisch
The Nina W. Werblow Charitable Trust
Estate of Robert L. Werner
Virginia A. Werner
Estate of E. Olga Wesner
Mrs. Elizabeth G. Weymouth
When Everyone Survives
Estate of Frank A. Widenski
Nancy P. Widner
Mr. and Mrs. Gene Wilder
Wilderness Point Foundation
The Wilf Family Foundation
Andrea J. Will Memorial Foundation
Barbara F. Williams
Mr. and Mrs. Eugene F. Williams III
Williams Trading LLC
Trust of Helen A. Wilson
The Winters Family Fund
Michel C. Witmer
Estate of James B. Wittrock
The Henry Wolf Foundation
Trust of Toby Wolfberg
Alice Aeschlman Wolfe
Mrs. Barbara Wolfson
Estate of Gordon Wootton
Deborah C. Wright
Trust of Twylia H. Wright
Estate of Bernadette Wyrrough
Ofer J. Yardeni
Mary and Bob Yellowlees
Estate of Arthur P. Young
Estate of Ellen Youngelson
Alfred D. Youngwood
Zegar Family Foundation
The Patricia J. and Edward W. Zeh Charitable Foundation
The Zickler Family Foundation
The Isaac Ziegler Charitable Trust
Stanley Shalom Zielony Foundation
Martha E. Zweig
Larry and Anne Zimmerman
“For nearly 70 years, members of The Society of MSK have made a difference in the lives of our patients. We’re grateful for the personal dedication they demonstrate and the important programmatic activities they enable.”

— CRAIG B. THOMPSON
President and CEO

“The Society is a unique part of the MSK team,” says Martha Vietor Glass, The Society President from 2013 to 2015. “We enjoy a dynamic partnership with MSK leadership to identify special needs of an immediate and long-term nature in both research and patient care. After we raise support through our members, our Administrative Board is excited to be able to fund projects that strengthen and enhance MSK’s mission.”

SUPPORTING RESEARCH

One of The Society’s central focuses is funding nascent research that is often too early to receive support from conventional sources. By sponsoring new and innovative research, The Society has helped launch the investigations of young scientists and has provided an opportunity for established researchers to explore leading-edge ideas.

In 2014, The Society’s Special Projects Committee funded the research of five MSK scientists. The projects included the development of a new way to combat drug resistance in cancer and a study using mouse models — complemented by analysis of human genetic data and tumor samples — to identify pathways that drive tumor progression in a childhood brain cancer called medulloblastoma.

The Society’s Research Grants support clinical and translational research projects, many of which go on to become permanent programs and features of MSK. In 2014, the grant program funded seven proposals. These included a study to evaluate whether genetic mutations can explain why some patients with lung cancer respond to immunotherapies while others don’t, a study that aims to enable clinicians to detect heart damage from chemotherapy before it becomes permanent, and research that will develop a novel pharmaceutical approach to ameliorate graft-versus-host (GvHD) disease in patients after allogeneic stem cell transplantation. GvHD occurs when a donor’s immune cells attack cells in a recipient’s body and can be a fatal complication of transplantation.

The Society also supports research through the Associates Committee Fall Party, which in 2014 raised funds to accelerate the launch and support of clinical trials of a treatment that promises to change the future of pediatric sarcoma.

The Annual Appeal, a tradition since 1946, supports research and sometimes patient care programs through a personal letter-writing campaign. This year, the Annual Appeal directed its efforts to funding research in leukemia and an exciting new way to fight the disease.
SUPPORTING PATIENT CARE

If any Society member were asked to define the other key purpose of the organization, the words “patient care” would echo again and again. The group has had a long-time commitment to enhancing the patient experience by providing activities and events outside of the treatment routine.

Patient programs that support artistic expression, special projects that brighten the patient environment, visits from Big Apple Circus clowns to the Department of Pediatrics, flowers in waiting areas, and festive holiday activities throughout the year are just some of the ways that The Society improves the days of MSK’s patients.

For decades, some of the most celebrated Society traditions have centered on making the winter holidays a joyful time for Memorial Hospital inpatients by sponsoring parties for both children and adults, complete with overflowing gift bags.

In May 2014, The Society hosted its seventh annual Spring Ball. The event raised funds for The Society’s Patient Assistance Program initiative, which provides emergency financial assistance to MSK patients to help with nonmedical expenses.

And in June, more than 200 pediatric patients — from toddlers to teens — partied up a storm at the annual Pediatric Prom. The event, hosted by The Society’s Children’s Committee, enables children and young adults who are being treated for cancer to celebrate with family, friends, and pediatric medical and support staff.

To increase accessibility and encourage support for its mission, The Society introduced its newest donor group, The Society Circle, in 2014.

1. The 24th annual Bunny Hop benefited MSK’s Department of Pediatrics.
2. (Left to right) Debra Pipines, 2014 Society Finance Committee Chairman; 2014 research grant recipients Matthew Hellman, MD, Paul Paik, MD, Sean McBride, MD, MPH, and Andrew Plodkowski, MD; MSK President and CEO Craig Thompson; MSK Physician-in-Chief José Baselga; Martin Voss, MD, Robert Young, MD, and Johannes Zakrzewski, MD, also recipients of 2014 research grants; and Society President Martha Vietor Glass.
3. Santa comes to MSK bearing holiday gifts.
4. Ms. Vietor Glass (center, in red) joins Spring Ball Chairmen (left to right) Alexi Meyers, Claudia Overstrom, Maria Villalba, and Lisa McCarthy.
THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER
ADMINISTRATIVE BOARD

EXECUTIVE COMMITTEE

MARTHA VIETOR GLASS  MRS. THOMAS S. GLOVER  DEBRA PIPINES  LAVINIA BRANCA SNYDER
President  Vice President  Vice President  Vice President

VICTORIA GREENLEAF KEMPNER  MRS. JAMES HALSEY BELL  MRS. THOMAS V. LEEDS
Treasurer  Assistant Treasurer  Past President

MRS. THOMAS M. FITZGERALD III  LESLIE HEANEY
Secretary  Assistant Secretary

MEMBERS-AT-LARGE

Muffie Potter Aston  Ruth G. Fleischmann  Stephanie Loeffler  Alexia Hamm Ryan
Mrs. Alan J. Blinken  Mrs. Lars Forsberg  Mrs. Roman Martinez IV  Mrs. Paul C. Schorr IV
Tory Burch  Mrs. Christopher P. Fuller  Mrs. S. Christopher Meigher III  Mrs. Stephen C. Sherrill
Mrs. Bryan J. Carey  Mrs. Robert M. Gardiner  Mrs. Richard A. Miller  Mrs. Sean Smith
Mrs. Michael Carr  Mrs. Mark V. Giordano  Mrs. George F. Moss  Mrs. Paul Soros
Mrs. Kevin C. Coleman  Eugenie Niven Goodman  Joyce L. Moss  Amanda Anne Cox Taylor
Mrs. Archibald Cox, Jr.  Mrs. Peter S. Gregory  Nancy Coffey Nagler  Mrs. Andrew S. Thomas
Jennifer Creel  Mrs. Roger P. Griswold, Jr.  Mrs. Timothy P. O’Hara  Mrs. Jerome L. Villalba
Mrs. Michael J.A. Darling  Grace W. Harvey  Jennifer Gaffney Oken  Victoria Vought
Mrs. Marvin H. Davidson  Melanie Holland  Mrs. Gunnar S Overstrom, III  Naomi Waletzky
Mrs. Hilary Dick  Mrs. Scott C. Johnston  Mrs. Richard T. Perkin  Alexis Robinson Waller
Webb Egerton  Robyn Lane Joseph  Mrs. Bambi Putnam  Mrs. Martha Webster
Mrs. Christopher Errico  Mrs. Michael Kennedy  Shafi Roepers  Mrs. Thomas E. Zacharias
MRS. THOMAS M. FITZGERALD III  LESLIE HEANEY
Secretary  Assistant Secretary

SUSTAINING BOARD

Courtney Arnot  Antonia Paepcke DuBrul  Suzie Kovner  Evelyn Angevine Silla
Mrs. Andres Bausili  Mrs. Thomas J. Fahey, Jr.  Mrs. Brian A. McCarthy  Mrs. Richard J. Sterne
Mrs. Andrew M. Blum  Mrs. Roberto de Guardiola  Suzanne McDonnell Long  Leith Rutherford Talamo
Dianne G. Crary  Mr. Kirk Henckels  Mrs. Minot K. Milliken  Mrs. Michael L. Tarnopol
Mrs. James F. Curtis III  Mrs. Peter K. Hills  Mrs. Charles H. Mott  Mrs. Douglas A. Warner III
Mrs. James H. Dean  Mrs. John S. Hilson  Mrs. Samuel M. Pryor IV  Mrs. Christopher Meigher III
Deborah A. DeCotis  Mrs. Ann F. Jeffery  Mrs. Benjamin M. Rosen  Mrs. Caryn Zucker

PRESIDENT’S COUNCIL

Mrs. Rand V. Araskog  Mrs. Charles A. Dana, Jr.  Mrs. Richard S. LeFrak  Linda Gosden Robinson
Nina Garcia Conrod  Julie Weindling Geier  Mrs. Donald B. Marron

PAST PRESIDENTS

Mrs. Coleman P. Burke  Mrs. Bruce A. Gimbel  Mrs. Arie L. Kopelman  Dr. Annette U. Rickel
Mrs. Edwin M. Burke  Mrs. William O. Harbach  Mrs. Derek L. Limbocker  Mrs. Bijan Safai
Mrs. William M. Carson  Alison Barr Howard  Jean Remmel Little  
Mrs. Walter B. Delafield  Mrs. Peter D. Jones  Mrs. M. Anthony May
Mrs. Charles H. Dyson  Mrs. Kerryn King  Mrs. Frank A. Metz, Jr.

FOUNDER

Mrs. Edward C. Delafield